Medical College of Wisconsin
CTSICores SearchResearch InformaticsREDCap

CURRICULUM VITAE

William R. Drobyski MD
Professor
Department of Medicine
Division of Hematology and Oncology - Medicine

OFFICE ADDRESS:
Froedtert East Clinics
9200 W Wisconsin Ave
Milwaukee, WI 53226

EDUCATION:
1975 - 1979 B.A., Brown University, Providence, Rhode Island
1979 - 1983 M.D., University of Rochester School of Medicine and Dentistry, Rochester, New York

POSTGRADUATE TRAINING AND FELLOWSHIP APPOINTMENTS:
1983 - 1984 Medical Internship, Strong Memorial Hospital, Rochester, NY
1984 - 1986 Medical Residency, Strong Memorial Hospital, Rochester, NY
1987 - 1988 Fellowship in Hematology, Strong Memorial Hospital, Rochester, NY
1988 - 1990 Fellowship in Bone Marrow Transplantation, Medical College of Wisconsin, Milwaukee, WI

FACULTY APPOINTMENTS:
1986 - 1987 Associate Attending, Emergency Department Clinical Instructor in Medicine, University of Rochester School of Medicine, Rochester, NY
1990 - 1994 Assistant Professor of Medicine, Medical College of Wisconsin, Milwaukee, WI
1991 - Present Full Member, Cancer Center, Medical College of Wisconsin, Milwaukee, WI
1994 - 2001 Associate Professor of Medicine, Medical College of Wisconsin, Milwaukee, WI
1999 - 2001 Associate Professor of Pediatrics (Joint Appointment), Medical College of Wisconsin, Milwaukee, WI
2001 - Present Professor of Medicine and Pediatrics (With Tenure), Medical College of Wisconsin, Milwaukee, WI
2005 - Present Professor of Microbiology and Molecular Genetics (Secondary Appointment), Medical College of Wisconsin, Milwaukee, WI
2010 - 2017 Program Leader, Hematologic Malignancy and Immunotherapy Program, Cancer Center, Medical College of Wisconsin, Milwaukee, WI
2010 - Present Scientific Director, Bone Marrow Transplant Program, Medical College of Wisconsin, Milwaukee, WI
2017 - Present Program Leader, Discovery and Developmental Therapeutics Program, Cancer Center, Medical College of Wisconsin, Milwaukee, WI
2018 - 2021 Steering Committee, Center of Immunology, Medical College of Wisconsin, Milwaukee, WI
2019 - Present Adjunct Senior Investigator, Versiti Blood Research Institute, Milwaukee, WI
2021 - Present Internal Advisory Board, Center of Immunology, Medical College of Wisconsin, Milwaukee, WI

ADMINISTRATIVE APPOINTMENTS:
1993 - 1998 Medical Consultant - The Blood Center of Southeastern Wisconsin, Molecular Diagnostics and Detection of Minimal Residual Disease, WI

HOSPITAL AND CLINICAL ADMINISTRATIVE APPOINTMENTS:
1990 - Present Staff Physician, Milwaukee County Medical Complex and Froedtert Memorial Lutheran Hospital, Milwaukee, WI
1993 - 1998 Medical Consultant, Versiti Blood Center of Southeastern Wisconsin, Molecular Diagnostics and Detection of Minimal Residual Disease, Milwaukee, WI

SPECIALTY BOARDS AND CERTIFICATION:
Board Certified
Issue DateExpiration
Internal Medicine
1986
2026
   
Licensure
Number Issue DateExpiration
Wisconsin License
29248-20
1988
2025
    

AWARDS AND HONORS:
1979 Phi Beta Kappa
1979 Magna Cum Laude
1980 Victor Meyer Emmel Prize in Medical Histology, (Inaugural Recipient)
1983 Alpha Omega Alpha
1983 M.D. with Honors
1991 - 1996 NIH Clinical Investigator Award
1995 Listed in Who's Who is Science and Engineering
1996 - 2001 NIH FIRST Award
1998 George Santos Prize for the best clinical paper published in Biology of Blood And Marrow Transplantation
2005 - 2006 Best Doctors in America
2007 - 2008 Best Doctors in America
2009 - 2010 Best Doctors in America
2011 - 2012 Best Doctors in America, 2011-2012
2011 Excellence in Research Award, Department of Medicine, Medical College of Wisconsin
2013 - 2014 Best Doctors in America
2015 - 2016 Best Doctors in America
2017 - Present Mariette C. and Philip W. Orth/Tom Anderson Endowed Chair in Oncology
2017 - 2018 Best Doctors in America
2018 Direct Election, Fellow of the American College of Physicians
2019 - 2020 Best Doctors in America
2019 Society of Research Excellence, Medical College of Wisconsin
2019 - 2020 MCW Outstanding Graduate School Educator, Medical College of Wisconsin
2020 Dean’s Award in Clinical and Translational Research (Unanimous Consent of the Committee), Medical College of Wisconsin
2022 - 2023 MCW Outstanding Graduate School Educator, Medical College of Wisconsin
2024 Elected to Fellowship, American Society of Transplantation and Cellular Therapy
2105 - 2017 Designated “Eminent Scholar”, (equivalent to an endowed chair), First MD at MCW to Receive this Honor, Medical College of Wisconsin

MEMBERSHIPS IN HONORARY AND PROFESSIONAL SOCIETIES:
American Society for Blood and Marrow Transplantation
American Society of Hematology

EDITORSHIPS/EDITORIAL BOARDS/JOURNAL REVIEWS:
Editorial Board
2001 - Present Biology of Blood and Marrow Transplantation
2004 - 2006 Leukemia
2017 - 2020 Blood
2018 - Present Associate Editor, Biology of Blood and Marrow Transplantation
2022 - Present Frontiers in Immunology, Associate Editor
Journal Review
1995 - Present Blood
1995 - Present Bone Marrow Transplantation
1997 - Present Biology of Blood and Marrow Transplantation
2002 - Present Journal of Immunology
2003 - Present Clinical Cancer Research
2003 - Present Experimental Hematology
2004 American Journal of Transplantation
2004 - Present Leukemia
2005 - Present Journal of Clinical Oncology
2007 Leukemia and Lymphoma
2007 Hematologica
2009 - Present European Journal of Immunology
2009 - Present Leukemia Research
2012 - Present Arthritis and Rheumatism
2013 - Present Virology Journal
2013 - Present Proceedings of the National Academy of Science (PNAS-USA)
2013 - Present Journal of Clinical Investigation
2017 - Present Science Translational Medicine
2017 - Present Nature Communications
2022 - Present Science Immunology
Transfusion
American Journal of Hematology

NATIONAL ELECTED/APPOINTED LEADERSHIP AND COMMITTEE POSITIONS:
1995 - 2004 Member, Subcommittee on Opportunistic Infections and Immune Reconstitution, Subcommittee on Chimerism, National Institutes of Health-Sponsored Study on T-cell Depletion in Unrelated Marrow Transplantation
1996 Session Moderator, "Biology of Engraftment", American Society of Hematology 38th Annual Meeting, Orlando, FL
1996 Abstract Reviewer, "Biology of Engraftment", American Society of Hematology 38th Annual Meeting, Orlando, FL
1997 Advisory Reviewer, Technology Assessment on "Donor leukocyte infusions for treatment of relapse of chronic myelogenous leukemia after bone marrow transplantation", American Medical Association
1997 Ad hoc Grant Reviewer, "Pathogenesis and diagnosis of novel human herpes viruses in bone marrow transplant recipients for primary immunodeficiency diseases", Comitato Promotore Telethon
1997 - 2011 Medical Director, Unrelated Marrow Transplant Program, Medical College of Wisconsin
1997 Ad hoc Merit Grant Reviewer, Veteran's Administration
1998 National Institute of Health, Ad hoc Reviewer, Experimental Therapy 1 Study Section
1998 Abstract Reviewer, "Experimental Transplantation-GVHD and Neoplasia", American Society of Hematology, 40th Annual Meeting, Miami Beach, FL
1999 Ad hoc Grant Reviewer, "Quantitative monitoring of immune response in patients following immunotherapy with donor lymphocyte infusion", Dutch Cancer Society
2000 Ad hoc Reviewer National Institute of Health, Special Emphasis Panel, SCOR in Transfusion Biology and Medicine, National Institute of Health
2000 - 2002 National Institute of Health, Ad hoc Reviewer, Experimental Therapeutics 2 Study Section
2001 - Present Scientific Board of Advisors, BMT InfoNet
2001 Abstract Reviewer, "Experimental Transplantation-Basic Biology, Regimens and Engraftment", American Society of Hematology, 43rd Annual Meeting, Orlando, FL
2002 - 2003 Member, Experimental Therapeutics 2 Study Section, National Institute of Health
2002 Session Moderator, "Experimental Transplantation-Basic Biology, Regimens and Engraftment", American Society of Hematology, 44th Annual Meeting, Philadelphia, PA
2002 Abstract Coordinating Reviewer, "Experimental Transplantation-Basic Biology, Regimens and Engraftment", American Society of Hematology, 44th Annual Meeting, Philadelphia, PA
2003 - 2005 Charter Member, Cancer Immunology Immunopathology Study Section, National Institute of Health
2004 Ad Hoc Grant Reviewer, Health Research Council of New Zealand
2005 Session Moderator, "Basic Biology, Engraftment and Immune Function", American Society of Hematology, 47th Annual Meeting, Atlanta, GA
05/11/2006 Ad Hoc Reviewer, "Allogeneic Hematopoietic Stem Cell Transplantation with Skewed Immune Reconstitution as a Cause of Autoimmunity", Swiss National Science Foundation
2007 Session Moderator, "Basic Biology, Engraftment and Immune Function", American Society of Hematology, 49th Annual Meeting, Atlanta, GA
2007 Abstract Reviewer, "Basic Biology, Engraftment and Immune Function", American Society of Hematology, 49th Annual Meeting, Atlanta, GA
2008 Task Force on Research Priorities, American Society of Bone Marrow Transplantation
04/30/2009 Ad hoc Grant Reviewer, "Effector and Regulatory CD4+ T cell Imbalance in Clinical Graft versus Host Disease", Medical Research Council
2009 Abstract Reviewer, "Experimental Transplantation-GVHD and GVL", American Society of Hematology, 51st Annual Meeting, New Orleans, LA
2009 Session Moderator, Experimental Transplantation - GVHD and GVL: Dissecting GvHD from GvL - The Promise of Lymphocyte Manipulation, American Society of Hematology, 51st Annual Meeting, New Orleans, LA
2010 Abstract Coordinating Reviewer, "Experimental Transplantation-Graft versus Host and Graft versus Leukemia", American Society of Hematology, 52nd Annual Meeting, Orlando, FL
11/15/2011 New Investigator Awards, American Society of Blood and Marrow Transplantation
12/19/2013 New Investigator Awards, American Society of Blood and Marrow Transplantation
2014 Advisory Board, “Use of Siltuximab for the Prevention of Acute Graft Versus Host Disease”, Janssen Research and Development
2015 - 2018 Member, (Vice Chair, 2017; Chair, 2018), Scientific Subcommittee on Immunology and Host Defense, American Society of Hematology
2015 Abstract Reviewer, “Experimental Transplantation-GVHD and GVL”, American Society of Hematology, 57th Annual Meeting, Orlando, FL
2017 - Present Board of Directors, American Society of Blood and Marrow Transplantation
2017 - Present Director of Laboratory Science, American Society of Blood and Marrow Transplantation
2017 Intramural Program Review, Experimental Immunology and Transplantation Branch, National Cancer Institute
01/24/2019 New Investigator Awards, American Society of Blood and Marrow Transplantation
03/07/2019 Special Emphasis Panel, National Institute of Dental and Craniofacial Research, National Institute of Health
2019 Abstract Coordinating Chair, "Graft versus Host Disease-Basic/Preclinical”, Transplantation and Cellular Therapy Meeting, Houston, TX
10/08/2020 Ad hoc Reviewer, Transplantation, Tolerance and Tumor Immunity Study Section, National Institute of Health
01/27/2021 New Investigator Awards, American Society of Blood and Marrow Transplantation
2021 - Present Committee on Awards, American Society of Transplantation and Cellular Therapy
11/10/2022 New Investigator Awards, American Society of Blood and Marrow Transplantation
11/07/2023 New Investigator Awards, American Society of Blood and Marrow Transplantation

RESEARCH GRANTS/AWARDS/CONTRACTS/PROJECTS:
Active
Peer Review
Title:
Medical College of Wisconsin, Mariette C. and Philip W. Orth/Tom Anderson Endowed Chair in Oncology
Source:
Endowed Chair Funds
Dates:
07/01/2017 - Present
Direct Funds:
$50,000 (Per year)
  
Title:
Phase II single center open label study for prevention of acute and chronic GVHD using Tocilizumab in combination with standard GVHD prophylaxis after allogeneic transplantation
Source:
Institutional
Role:
Co-Principal Investigator
Dates:
11/01/2018 - Present
  
Title:
A Phase 2 Trial of Tildrakizumab for the Prevention of Graft Versus Host Disease
Source:
Institutional
Role:
Co-Principal Investigator
Dates:
11/04/2019 - Present
  
Title:
NIH/NHLBI R01 154579, “Mechanistic Inflammatory Pathways in Graft Versus Host Disease”
Source:
Multi-PI Grant (with Cecilia Hillard, PhD)
Role:
Contact Principal Investigator
PI:
Drobyski, William
Dates:
08/01/2020 - 05/31/2025
Direct Funds:
$1,792,288
  
Title:
“Blockade of IL-23 for the Prevention of Graft Versus Host Disease”
Source:
NIH/NHLBI R01 HL153192
Role:
Principal Investigator
PI:
Drobyski, William
Dates:
04/15/2021 - 03/31/2025
Direct Funds:
$1,406,046
  
Title:
“Inflammatory cytokine networks in gastrointestinal tract graft versus host disease”
Source:
NIH/NHLBI R01 126166
Role:
Principal Investigator
PI:
Drobyski, William
Dates:
12/01/2023 - 11/30/2027
Direct Funds:
$1,520,314
  
Pending
Peer Review
Title:
"The Role of Nitric Oxide in Hematopoietic Reconstitution in Mice Undergoing GVHD After Allogeneic Marrow Transplantation"
Source:
Falk Foundation Merit Award
Role:
Principal Investigator
PI:
Drobyski, William
Dates:
01/01/1995 - 12/31/1995
Direct Funds:
$20,000
  
Title:
“Role of  T cells in Alloengraftment and GVHD”
Source:
American Medical Association, Florence Carter Fellowship in Leukemia Research
Role:
Principal Investigator
PI:
Drobyski, William
Dates:
07/01/1996 - 06/30/1997
Direct Funds:
$25,000
  
Title:
“PD-1/B7-H1 Blockade to Increase Vaccine Efficacy for Myeloma”
Source:
MCW Interdisciplinary Cancer Research Fellowship Award
Role:
Co-Investigator
PI:
Johnson, Byron
Dates:
01/01/2010 - 12/31/2010
Direct Funds:
$50,000
  
Title:
Medical College of Wisconsin Cancer Center, “Tocilizumab for the Prevention of Acute Graft Versus Host Disease”
Source:
Kurtis Froedtert Foundation Award
Role:
Co-Principal Investigator
Dates:
11/01/2014 - 10/31/2017
Direct Funds:
$15,000
  
Prior
Peer Review
Title:
"Molecular Detection of Leukemia After Allogeneic BMT"
Source:
American Cancer Society, Institutional Research Grant
Role:
Principal Investigator
PI:
TDC
Dates:
07/01/1990 - 06/30/1991
Direct Funds:
$7,500
  
Title:
"Molecular Detection of Leukemia After Allogeneic BMT"
Source:
NIH/NCI Grant K08-CA-01534
Role:
Principal Investigator
PI:
Drobyski, William
Dates:
09/18/1991 - 08/31/1995
Direct Funds:
$385,000 (75% Effort)
  
Title:
Phase I/II Study of Donor Leukocyte Infusions as a Treatment for Patients with Relapsed Hematologic Malignancies Occurring after Allogeneic Bone Marrow Transplantation from an HLA Matched Sibling Donor
Source:
Institutional
Role:
Principal Investigator
PI:
Drobyski, William
Dates:
12/18/1991
  
Title:
"Pathogenicity of HHV-6 in Marrow Transplantation"
Source:
American Cancer Society Grant EDT 19
Role:
Co-Principal Investigator
Dates:
07/01/1992 - 08/31/1995
Direct Funds:
$204,000 (15% effort)
  
Title:
Allogeneic Marrow Transplantation for Patients with Hematologic Malignancies and Marrow Failure States from Genotypically Haploidentical Family Donors
Source:
Institutional
Role:
Principal Investigator
PI:
Drobyski, William
Dates:
02/04/1993
  
Title:
“Therapy Groups to Study T-cell Depletion in Unrelated Donor Marrow Transplantation”
Source:
NHLBI, N01 HB47097
Role:
Co-Investigator
Dates:
11/01/1993 - 01/01/1996
Direct Funds:
$524,160 (10% effort)
  
Title:
Medical College Wisconsin Cancer Center, "The Role of Nitric Oxide in Hematopoietic Reconstitution in Mice Undergoing GVHD After Allogeneic Marrow Transplantation"
Dates:
07/01/1994 - 06/30/1996
Direct Funds:
$10,000
  
Title:
Adoptive Immunotherapy for Leukemia and Lymphoproliferative Disorders: Done Lymphocytes Transduced with the Herpes Simplex Thymidine Kinase Gene for Remission induction (HGTR10103)
Source:
Collaboration with Northwestern University and Human Gene Therapy Institute, Des Moines, Iowa
Role:
Principal Investigator
PI:
Drobyski, William
Dates:
04/23/1996
  
Title:
“Role of  T cells in Alloengraftment and GVHD”
Source:
NIH/NHLBI Grant R29-HL55388
Role:
Principal Investigator
PI:
Drobyski, William
Dates:
09/01/1996 - 08/31/2001
Direct Funds:
$350,000
  
Title:
“Role of Gamma Delta T Lymphocytes in Alloengraftment and Graft-versus-Host Disease”
Source:
Mallinckrodt Foundation
Role:
Principal Investigator
PI:
Drobyski, William
Dates:
03/01/1997 - 02/28/2000
Direct Funds:
$155,000 (15% effort)
  
Title:
“T Cell Apoptosis: A Strategy to Reduce GVHD and Preserve Engraftment After Allogeneic BMT”
Source:
American Cancer Society
Role:
Principal Investigator
PI:
Drobyski, William
Dates:
01/01/1998 - 02/28/2000
Direct Funds:
$304,000
  
Title:
“Facilitation of Bone Marrow Engraftment without Graft-Versus- Host Disease in Mice using a Suicide Gene Expressed in T Cells”
Source:
Culpeper Foundation
Role:
Principal Investigator
PI:
Drobyski, William
Dates:
01/01/1998 - 12/31/2000
Direct Funds:
$100,000 (10% Effort)
  
Title:
 “Modulating GVH/GVL Post BMT Using TK Expressing T Cells”
Source:
NIH/NHLBI R01-HL63603
Role:
Principal Investigator
PI:
Drobyski, William
Dates:
04/01/2000 - 03/31/2007
Direct Funds:
$1,125,000 (Two years, no cost-extension)
  
Title:
“Allospecific immunoregulatory T cells in BMT recipients”
Source:
NIH/NIAID R21-HL69721
Role:
Co-Investigator
Dates:
07/01/2001 - 06/30/2004
Direct Funds:
$450,000 (5% Effort)
  
Title:
“Modulation of GVL and GVHD using TK Expressing T cells”
Source:
MACC Fund
Role:
Principal Investigator
PI:
Drobyski, William
Dates:
07/01/2001 - 06/30/2002
Direct Funds:
$15,000
  
Title:
LLME Treated Cellular Immunotherapy Following T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation for Acceleration of Immune Reconstitution
Source:
Thomas Jefferson University/Medical College of Wisconsin
Role:
Principal Investigator
PI:
Drobyski, William
Dates:
04/01/2002 - 09/19/2006
  
Title:
“Modulation of GVL and GVHD using TK Expressing T cells”
Source:
MACC Fund
Role:
Principal Investigator
PI:
Drobyski, William
Dates:
07/01/2002 - 06/30/2003
Direct Funds:
$15,000
  
Title:
“Regulation of alloengraftment and immunity by gamma delta T cells”
Source:
NIH/NHLBI R01-HL55388
Role:
Principal Investigator
PI:
Drobyski, William
Dates:
07/01/2002 - 06/30/2006
Direct Funds:
$900,000 (20% Effort)
  
Title:
A Research Database for Allogeneic Unrelated Hematopoietic Stem Cell Transplantation
Source:
National Marrow Donor Program
Role:
Principal Investigator
PI:
Drobyski, William
Dates:
09/30/2002 - 2011
  
Title:
Contribution of a Blood Sample to the National Marrow Donor Program’s Research Sample Repository
Source:
National Marrow Donor Program
Role:
Principal Investigator
PI:
Drobyski, William
Dates:
10/07/2002 - 2011
  
Title:
Haploidentical Hematopoietic Stem Cell Transplantation (HCT) Using Highly Purified Hematopoietic Stem Cells
Source:
Institutional
Role:
Principal Investigator
PI:
Drobyski, William
Dates:
12/16/2002 - 2010
  
Title:
“Modulation of GVL and GVHD using TK Expressing T cells”
Source:
MACC Fund
Role:
Principal Investigator
PI:
Drobyski, William
Dates:
07/01/2003 - 06/30/2004
Direct Funds:
$18,500
  
Title:
Advancing a Healthier Wisconsin, Medical College of Wisconsin Consortium on Public and Community Health, “Role of T Regulatory Cells in Graft Vs Host Disease and Tumor Clearance”
Role:
Co-Investigator
PI:
Grossman, William
Dates:
07/01/2004 - 06/30/2007
Direct Funds:
$750,000
  
Title:
“Immunobiology of Bone Marrow Transplantation”
Source:
MACC Fund
Role:
Principal Investigator
PI:
Drobyski, William
Dates:
07/01/2004 - 06/30/2005
Direct Funds:
$18,500
  
Title:
Compassionate use Protocol for the Use of AMD3100 to Mobilize Peripheral Blood Stem Cells for the Collection and Transplantation
Source:
Anormed (AMD 3100 CU)
Role:
Principal Investigator
PI:
Drobyski, William
Dates:
06/14/2005 - 2009
  
Title:
“Immunobiology of Bone Marrow Transplantation”
Source:
MACC Fund
Role:
Principal Investigator
PI:
Drobyski, William
Dates:
07/01/2005 - 06/30/2006
Direct Funds:
$21,000
  
Title:
“NK Cells, Their Receptors and Unrelated Donor Transplantation” Project 3, A Multicenter Prospective Trial to Evaluate the Role of NK Cell KIR Epitope Mismatch on Morality and Disease Relapse in T Cell Depleted Hematopoietic Stem Cell Transplantation in HLA-C Mismatched Unrelated Donors for Myeloid Malignancies
Source:
NIH/NCI P01-CA111412
Role:
Co-Investigator
PI:
Subcontract through University of Minnesota
Dates:
08/17/2005 - 07/31/2010
Direct Funds:
$28,431 (5% Effort)
  
Title:
Ridin for Research Foundation, “Graft versus Host Disease and Autoimmunity”
Source:
TDC
Role:
Principal Investigator
PI:
Drobyski, William
Dates:
04/01/2006 - 03/31/2007
Direct Funds:
$25,000
  
Title:
MCW Cancer Center, Interdisciplinary Grant, “Immunotherapy for Myeloma early after Hematopoietic Stem Cell Transplantation”
Source:
TDC
Role:
Co-Investigator
PI:
Johnson, Bryon
Dates:
07/01/2006 - 06/30/2007
Direct Funds:
$25,000
  
Title:
“Augmenting GVL Reactivity without GVHD”
Source:
Will Ross Memorial Foundation
Role:
Principal Investigator
PI:
Drobyski, William
Dates:
07/01/2006 - 06/30/2008
Direct Funds:
$25,000
  
Title:
“Graft versus Host Disease and Autoimmunity”
Source:
MACC Fund
Role:
Principal Investigator,
PI:
Drobyski, William
Dates:
07/01/2006 - 06/30/2007
Direct Funds:
$20,000
  
Title:
“Graft Versus Host Disease and Autoimmunity”
Source:
NIH/NHLBI R01 081650
Role:
Principal Investigator
PI:
Drobyski, William
Dates:
03/01/2007 - 02/28/2012
Direct Funds:
$1,250,000 (15 % Effort)
  
Title:
“Augmenting GVL Reactivity without GVHD”
Source:
NIH/NHLBI R01 64603
Role:
Principal Investigator
PI:
Drobyski, William
Dates:
07/01/2007 - 06/30/2012
Direct Funds:
$1,000,000 (20% Effort)
  
Title:
“Immunotherapy for Myeloma after Hematopoietic Stem Cell Transplantation”
Source:
MACC Fund
Role:
Principal Investigator
PI:
Drobyski, William
Dates:
09/01/2007 - 08/31/2010
Direct Funds:
$225,000
  
Title:
A Single Arm Phase II Trial of Transplantation of HLA-Identical Sibling CD34+ Enriched Peripheral Blood Stem Cells Isolated by the Isolex System with a Fixed T Cell Dose in the Treatment of Patients with Hematological Malignancies.
Source:
Institutional
Role:
Principal Investigator
PI:
Drobyski, William
Dates:
11/28/2007
  
Title:
Opportunity Fund for Translational Research, “Use of Lentivirus-Based Vectors for Improving the Safety of DLI-Based Therapy after BMT”
Source:
 MACC Fund
Role:
Principal Investigator
PI:
Drobyski, William
Dates:
12/01/2007 - 11/30/2013
Direct Funds:
$450,000
  
Title:
“Immunobiology of Bone Marrow Transplantation”
Source:
MACC Fund
Role:
Principal Investigator
PI:
Drobyski, William
Dates:
07/01/2009 - 06/30/2010
Direct Funds:
$25,000
  
Title:
“Role of Interleukin 23 in Graft versus Host and Graft versus Leukemia Reactivity”,
Source:
MCW Post-Doctoral Research Fellowship Award
Role:
Mentor for Rupali Das PhD, Post-Doctoral Student
Dates:
07/01/2009 - 12/30/2010
Direct Funds:
$50,000
  
Title:
“Interleukin 23 as a therapeutic target for Leukemia Treatment”
Source:
Lady Tata Award
Role:
Mentor for Rupali Das PhD, Post-Doctoral Student
Dates:
10/01/2009 - 09/30/2010
Direct Funds:
$31,690 (award subsequently withdrawn due to post-doc re-location)
  
Title:
Pre-Clinical Studies on Vaccines from Patient-derived Myeloma Samples
Source:
Institutional
Role:
Principal Investigator
PI:
Drobyski, William
Dates:
2009 - 2016
  
Title:
“Role of Interleukin 23 in the Pathophysiology of GVH and GVL Reactivity”
Source:
NIH/NIDDK R01 083358
Role:
Principal Investigator
PI:
Drobyski, William
Dates:
04/01/2010 - 11/30/2015
Direct Funds:
$872,500 (15% Effort)
  
Title:
“Graft versus Host Disease and Autoimmunity”
Source:
MACC Fund
Role:
Principal Investigator
PI:
Drobyski, William
Dates:
07/01/2010 - 06/30/2011
Direct Funds:
$15,000
  
Title:
Presence of Interleukin 23 in Histopathological Samples from Patients with Graft versus Host Disease
Source:
Institutional
Role:
Principal Investigator
PI:
Drobyski, William
Dates:
03/03/2011 - 2016
  
Title:
“Immunobiology of Bone Marrow Transplantation”
Source:
MACC Fund
Role:
Principal Investigator
PI:
Drobyski, William
Dates:
07/01/2011 - 06/30/2012
Direct Funds:
$15,000
  
Title:
Phase I-II Study Using Tocilizumab for the Treatment of Steroid Refractory Graft versus Host Disease
Source:
Institutional
Role:
Principal Investigator
PI:
Drobyski, William
Dates:
07/13/2011 - 02/17/2016
  
Title:
Retrospective Analysis of Autologous Graft versus Host Disease
Source:
Institutional
Role:
Principal Investigator
PI:
Drobyski, William
Dates:
09/20/2011 - 2015
  
Title:
Hematologic Malignancy and Transplantation Program
Source:
Advancing a Healthier Wisconsin Research and Education Award
Role:
Program Leader
Dates:
11/01/2011 - 10/31/2016
Direct Funds:
$4,985,422
  
Title:
“Tumor vaccine and Immune Modulating Agents to Optimize Anti-tumor Immunity”
Source:
Clinical Translational Scientist Institute Award
Role:
Co-Investigator
PI:
Gershan, Jill
Dates:
04/01/2012 - 03/31/2013
Direct Funds:
$20,000
  
Title:
“Regulatory T Cell Populations in Graft Versus Host Disease”
Source:
MACC Fund
Role:
Principal Investigator
PI:
Drobyski, William
Dates:
07/01/2012 - 06/30/2013
Direct Funds:
$79,467
  
Title:
“Role of Retinoic Acid in Graft versus Host Disease”
Source:
Amy Strelzer Manasevit Scholar Award
Role:
Mentor for Dr Xiao Chen MD PhD
Dates:
07/01/2012 - 06/30/2015
Direct Funds:
$240,000
  
Title:
“Regulatory T Cell Populations in Graft versus Host Disease”
Source:
NIH/NHLBI R01 064603
Role:
Principal Investigator
PI:
Drobyski, William
Dates:
05/27/2013 - 01/31/2018
Direct Funds:
$988,000
  
Title:
“Graft versus Host Disease and Autoimmunity”
Source:
MACC Fund
Role:
Principal Investigator
PI:
Drobyski, William
Dates:
07/01/2013 - 06/30/2014
Direct Funds:
$97,207
  
Title:
Medical College of Wisconsin, Department of Medicine, Eminent Scholar in Research
Source:
Endowed Chair Funds
Dates:
07/01/2014 - 06/30/2017
Direct Funds:
$40,000 (Per year)
  
Title:
“Role of Interleukin 23 in the Biology of Graft Versus Host Disease”
Source:
MACC Fund
Role:
Principal Investigator
PI:
Drobyski, William
Dates:
07/01/2014 - 06/30/2015
Direct Funds:
$109,454
  
Title:
Immune Checkpoint Protein Expression on Marrow Cells from Patients with Multiple Myeloma
Source:
Institutional
Role:
Principal Investigator
PI:
Drobyski, William
Dates:
07/25/2014 - 2017
  
Title:
Phase 2 Open Label Trial of Tacrolimus/Methotrexate and Tocilizumab for the Prevention of Acute Graft Versus Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation
Source:
Institutional
Role:
Principal Investigator
PI:
Drobyski, William
Dates:
12/07/2014 - 2019
  
Title:
Medical College of Wisconsin, “Effect of Inflammation on Cognition, Behavior, and Psychiatric Illness”,
Source:
Advancing a Healthier Wisconsin Research and Education Program Grant
Role:
Principal Investigator
PI:
Drobyski, William
Dates:
07/01/2015 - 06/30/2017
Direct Funds:
$200,000
  
Title:
“Role of Interleukin 23 in Gastrointestinal GVHD”
Source:
NIH/NHLBI R01 126166
Role:
Principal Investigator
PI:
Drobyski, William
Dates:
08/01/2015 - 04/30/2019
Direct Funds:
$1,000,000
  
Title:
“Cannabinoid-mediated mitigation of graft versus host disease: Role of CB2 receptors and adenosine signaling”
Source:
NIH/NHLBI R01 139008
Role:
Multi-PI grant, Contact Principal Investigator
PI:
Hillard, Cecilia
Dates:
08/01/2017 - 06/30/2022
Direct Funds:
$1,405,200
  
Title:
Effect of GVHD on Brain Function
Source:
MCW Cancer Center Multi-PI Pilot Grant
Role:
Co-Principal Investigator
Dates:
12/01/2017 - 11/30/2017
Direct Funds:
$50,000
  
Title:
Phase 1 Study of Nivolumab in combination with Tocilizumab for Treatment of Patients with Relapsed Hematological Malignancies Post-Allogeneic Transplant
Source:
Institutional
Role:
Co-Principal Investigator
Dates:
09/12/2018 - 2020
  
Title:
“The Role of donor T cell-derived GM-CSF in the pathogenesis of Gastrointestinal acute GVHD”
Source:
NIH/NHLBI F30 143870
Role:
Sponsor
PI:
Piper, Clint
Dates:
10/01/2018 - 09/31/2022
Direct Funds:
$180,096
  
Title:
“Inflammatory cytokine networks in gastrointestinal tract graft versus host disease”
Source:
NIH/NHLBI R01 126166
Role:
Principal Investigator
PI:
Drobyski, William
Dates:
05/01/2019 - 04/30/2024
Direct Funds:
$1,311,416
  

INVITED LECTURES/WORKSHOPS/PRESENTATIONS:
Local
"Preservation of Lymphokine-Activated Killer Activity after Allogeneic Bone Marrow Transplantation", MACC Fund Site Visit, Milwaukee, WI, 1992
"Treatment Strategies for Resistant CML in the Transplant and Nontransplant Settings", Milwaukee Blood Club, Milwaukee, WI, 1993
"Donor Leukocyte Infusions: Current Applications and Future Strategies", Hematology/Oncology Grand Rounds, Medical College of Wisconsin, Milwaukee, WI, 1999
"Use of Gamma Delta T cells as a Novel Transplantation Strategy to Promote Engraftment without Graft-Versus-Host Disease", Department of Pediatric Academic Conference, Medical College of Wisconsin, Milwaukee, WI, 2000
"Regulation of Alloresponses after Allogeneic Stem Cell Transplantation using Thymidine Kinase Gene Modified Donor T Cells", Department of Microbiology and Molecular Genetics Seminar Series, Medical College of Wisconsin, Milwaukee, WI, 08/31/2004
"Pivotal Role of Interleukin 23 in Allogeneic Stem Cell Transplantation", Research Conference, Children's Research Institute, Medical College of Wisconsin, Milwaukee, WI, 06/11/2010
“Pivotal Role of Interleukin 23 in Gastrointestinal Graft Versus Host Disease”, Third Annual Committee on Immunology Conference, Medical College of Wisconsin, Milwaukee, WI, 09/16/2011
“Pivotal Role of Interleukin 23 in the Pathophysiology of Graft versus Host Disease”, Medical College of Wisconsin Infectious Disease Research Conference, Medical College of Wisconsin, Milwaukee, WI, 09/06/2012
“Defining critical proinflammatory pathways in Graft versus Host Disease: Basic mechanisms and translational initiatives”, MACC Fund Professor Candidate Talk, Medical College of Wisconsin, Milwaukee, WI, 01/30/2014
“Identification of a Colitogenic Memory CD4+ T Cell Population that Mediates Gastrointestinal Tract GVHD”, Committee on Immunology Conference, Versiti Blood Research Institute, Milwaukee, WI, 10/26/2016
“Interleukin 6 regulates inflammation and behavioral function in the brain during graft versus host disease”, Department of Medicine Annual Retreat, Medical College of Wisconsin, Milwaukee, WI, 03/10/2017
“Effect of Inflammation on Cognition, Behavior, and Psychiatric Illness”, Change makers in Science REP Annual Symposium, Advancing a Healthier Wisconsin, Medical College of Wisconsin, Milwaukee, WI, 07/19/2017
“Graft versus Host Disease”, MCW Cancer Center Advisory Board, Medical College of Wisconsin, Milwaukee, WI, 09/13/2017
“Biology of Graft versus Host Disease”, Medical Student Oncology Interest Group, Medical College of Wisconsin, Milwaukee, WI, 04/27/2018
“Signaling through the Type 2 Cannabinoid Receptor regulates the Severity of Acute and Chronic Graft versus Host Disease”, Bone Marrow Transplantation and Cellular Therapy Education Session, Medical College of Wisconsin, Milwaukee, WI, 12/10/2020
“Promoting Research and Clinical Collaborations-Challenges and Opportunities”, Faculty Development Seminar, Department of Obstetrics and Gynecology, Medical College of Wisconsin, Milwaukee, WI, 11/30/2022
“Inflammatory Cytokine Pathways in Gastrointestinal Tract Graft Versus Host Disease”, Cancer Center Grand Rounds, Medical College of Wisconsin, Milwaukee, WI, 03/03/2023
 
Regional
“Regulation of Gastrointestinal Inflammation during Graft Versus Host Disease by Interleukin 23”, Comprehensive Cancer Center Seminar Series, City of Hope Cancer Center, Duarte, CA, 06/06/2016
“Inflammatory Cytokine Networks in the Gastrointestinal Tract during Graft Versus Host Disease", Immunology Work In Progress Seminar Series, University of Wisconsin, Madison, WI, 03/02/2021
 
National
"Role of Human Herpesvirus Six Infection in Bone Transplant Recipients", ASTRA Pharmaceutical Conference on Herpesvirus Infections in Immunocompromised Patients, Westboro, MA, 1991
"Human Herpesvirus Six Infection in Bone Marrow Transplant Recipients", UCLA Keystone Symposium on Bone Marrow Transplantation, Keystone, CO, 1994
"The Role of Donor Leukocyte Infusions in Unrelated Marrow Transplantation", National Institute of Health Workshop on GVHD in Unrelated Bone Marrow Transplantation, Bethesda, MD, 1994
"Use of Unrelated Donors in Allogeneic Bone Marrow Transplantation", University of Rochester, City Wide Hematology Conference, Rochester, NY, 1994
"Unrelated Donors in Allogeneic Bone Marrow Transplantation", Washington University, St Louis, MO, 1994
Adoptive Immunotherapy Using Donor Leukocyte Infusions as Treatment for Relapsed Disease after Allogeneic BMT, Baylor University, Dallas, TX, 1995
Donor lymphocyte infusions for relapsed leukemia, Sixth Annual Malnati Symposium in the Clinical Sciences: "Hematopoietic Stem-Cell Transplantation: Advances and Controversies", Northwestern University Medical School, Chicago, IL, 1996
"Biology and Therapy of Bacterial and Fungal Infections in Leukemia, Lymphoma and Bone Marrow Transplantation", Symposium, San Diego, CA, 1998
"The Case for T Cell Depletion in the Treatment of Chronic Phase Chronic Myelogenous Leukemia After Allogeneic Bone Marrow Transplantation", IBMTR/ABMTR Annual Meeting, Anaheim, CA, 2000
"Transplant Outcomes in Unrelated versus Haploidentical Marrow Transplant Recipients", National Marrow Donor Program Annual Meeting, Minneapolis, MN, 2001
“The Regulation of Alloresponses after Bone Marrow Transplantation using Donor T cells Expressing a Thymidine Kinase Suicide Gene”, Translational Research Conference, NCI-Frederick, Frederick, MD, 2002
"Regulating immune responses after allogeneic bone marrow transplantation using donor T cells expressing a thymidine kinase suicide gene", University of Rochester, Rochester, NY, 2002
"How Good is Allogeneic Transplantation for High Risk AML?", Acute Leukemia Forum 2004: "Advances in the Biology and Therapy of Acute Myelogenous Leukemia", San Francisco, CA, 04/16/2004
"Convergence of Alloreactivity and Autoreactivty during the Transition from Acute to Chronic Graft versus Host Disease", University of Miami, Miami, FL, 05/30/2007
"Targeting NFKB for the Prevention of Graft versus Host Disease", Celgene Inflammation Symposium, San Diego, CA, 06/13/2008
"Role on Interleukin 23 in graft versus host disease and graft versus leukemia reactivity after allogeneic stem cell transplantation", Merck/BioSchering Pharma Symposium of the Biology of Interleukin 23, Palo Alto, CA, 02/01/2010
"Restrictions on peripheral T cell reconstitution during graft versus host disease", Scientific Session on Immune Reconstitution, How it should work, why it is broken and why it matters, American Society of Blood and Marrow Transplantation, Orlando, Florida, 02/27/2010
"Pivotal Role of Interleukin 23 in Allogeneic Stem Cell Transplantation", Bone Marrow Transplant Grand Rounds, Moffitt Cancer Center, Tampa, FL, 04/12/2011
“Role of Interleukin 23 in Graft Versus Host Disease Biology”, Merck Pharmaceutical Scientific Input Engagement Meeting on Graft Versus Host Disease, Newark, New Jersey, 03/08/2013
“Role of Interleukin 23 in Mediating Colonic Inflammation during Graft versus Host Disease”, Boehringer Ingelheim Research Conference, Ridgefield, CT, 08/21/2013
“Inhibition of Interleukin 23 signaling as a strategy to separate graft versus host from graft versus leukemia responses", Symposium on Strategies to inhibit graft versus host disease while sparing the graft versus tumor response: Finding the sweet spot, Biochemical Pharmacology Discussion Group, New York Academy of Sciences, New York, NY, 02/18/2014
“The Role of Stat3 Dependent Cytokines in Gastrointestinal GVHD”, Scientific Session on Graft versus Host Disease: Emerging concepts in Gastrointestinal GVHD, American Society of Blood and Marrow Transplantation, Dallas, Texas, 02/26/2014
“Rationale for the Selection and use of Gamma Delta T cells in Haploidentical Stem Cell Transplantation”, Haploidentical Transplantation 2015, Orlando, FL, 12/02/2015
“Identification of a Colitogenic Memory CD4+ T Cell Population that is regulated by Interleukin 23 and Mediates Gastrointestinal Tract GVHD”, Hematology/Oncology Research Conference, University of Michigan, Ann Arbor, MI, 01/26/2017
“Preclinical and Clinical Strategies for the Prevention of Gastrointestinal Tract Graft Versus Host Disease”, Department of Microbiology and Immunology Research Conference, Temple University, Philadelphia, PA, 04/04/2017
“Host interleukin 6 production regulates inflammation but not tryptophan metabolism in the brain during murine GVHD”, Midwest Brain, Behavior, and Immunity Meeting, Chicago, IL, 12/01/2017
“Inflammatory Cytokine Networks in the Gastrointestinal Tract during Graft Versus Host Disease”, BMT/CTT Research Seminar Series, University of Pennsylvania, Philadelphia, PA, 04/15/2021
“Inflammatory Cytokine Networks in the Gastrointestinal Tract during Graft Versus Host Disease”, Thomas E. Starzl Transplantation Biology Seminar Series, University of Pittsburgh, Pittsburg, PA, 11/19/2021
“Inflammatory Cytokine Pathways in Gastrointestinal Tract Graft Versus Host Disease”, Purdue University Center for Cancer Research Seminar Series, West Lafayette, IN, 03/10/2022
 

COMMITTEE SERVICE:
Medical College of Wisconsin
1991 - 1999 Fellowship Evaluation Committee, Hematology/Oncology, Medicine, Medical College of Wisconsin
1992 - 1998 Bone Marrow Transplant Program Strategic Planning Committee, Medical College of Wisconsin
1992 - 1995 Medical College of Wisconsin Cancer Center Scientific Review Committee, Medical College of Wisconsin
1994 - 1995 Director, Search Committee, Bone Marrow Transplant Program, Medical College of Wisconsin
1995 - 1996 Research Task Force, MCW Institutional Strategic Planning Committee, Medical College of Wisconsin
1996 - 2013 MCW Cancer Center Grants Review Committee, Medical College of Wisconsin
2000 - 2002 MCW Medical Student Research Honors Program Committee, Medical College of Wisconsin
2005 - Present MCW Committee on Immunology, Medical College of Wisconsin
2006 - 2013 MCW Immunotherapy of Cancer Committee, Medical College of Wisconsin
2006 - 2009 MCW In Vivo Core Imaging Committee, Medical College of Wisconsin
2007 - 2009 Member, Internal Review Board (IRB), Committee #3, Medical College of Wisconsin
2009 Fellowship Interview Committee, Neoplastic Diseases, Medical College of Wisconsin
2010 - 2011 Search Committee, Pediatric Hematology/Oncology, Medical College of Wisconsin
2010 - 2011 Executive Committee, Clinical Translation Science Institute, Mentoring Initiative, Medical College of Wisconsin
2014 American Cancer Society Institutional Research Grant Committee, Medical College of Wisconsin
2014 - 2019 MCW Cancer Center Basic Biology Seed Grant Committee, Medical College of Wisconsin
2014 MCW Cancer Center Translational Research Committee, Medical College of Wisconsin
2014 - 2017 Children’s Research Institute Pilot Grant Review Committee, Medical College of Wisconsin
2015 - 2019 MCW Cancer Center Flow Cytometry Review Committee, Medical College of Wisconsin
2015 Advancing a Healthier Wisconsin, Research and Education Grant Review Committee, Medical College of Wisconsin
2016 - Present Biomedical Resource Center Advisory Committee, Medical College of Wisconsin
2016 Search Committee, MCW Chair of Microbiology and Molecular Genetics, Medical College of Wisconsin
2016 - 2020 MCW Cancer Center Education and Training Committee, Medical College of Wisconsin
2017 Therapeutic Accelerator Program Review Committee, Medical College of Wisconsin
2017 - 2018 Search Committee, Stem Cell Biology Program,, Versiti Blood Research Institute
2018 Genomic Sciences and Precision Medicine Center Seed Grant Review Committee, Medical College of Wisconsin
2018 - 2019 Center for Immunology Grant Review Committee, Medical College of Wisconsin
2019 - 2020 Chair, Immunotherapy Program Faculty Search Committee, Medical College of Wisconsin
2019 - 2020 MCW Chair of Pharmacology, Search Committee, Medical College of Wisconsin
2019 Children’s Research Institute Pilot Grant Review Committee, Medical College of Wisconsin
2020 - 2021 Advancing a Healthier Wisconsin, Collaborative Research for Improved Health Grant Review Committee, Medical College of Wisconsin
2020 - 2021 Cancer Research Building Vivarium Focus Committee, Medical College of Wisconsin
2021 - Present Scholarship Committee, Translational Research in Immuno Oncology Training Program, Medical College of Wisconsin
2021 - Present Cell Therapy Immune Monitoring Core Advisory Committee, Medical College of Wisconsin
2021 - Present MCW Office of Research Advancing a Healthier Wisconsin, Program Project Grant Review Committee, Medical College of Wisconsin
2021 - 2022 MCW Cancer Center Pilot Grant Review Committee, Medical College of Wisconsin
2022 - Present MCW Bone Marrow Bank Utilization Committee, Medical College of Wisconsin
2022 Cancer Center Fellowship Review Committee, Medical College of Wisconsin
 
Hospital
1993 - 1997 Transfusion Committee
 

MEDICAL COLLEGE TEACHING ACTIVITIES:
Medical Student Education
1990 MCW Bone Marrow Transplant Grand Rounds, "Human Herpesvirus-6 (HHV-6) Infections in BMT Patients"
1990 - 1992 Director, Bone Marrow Transplant Grand Rounds
1990 Attend two-four months/year on the Bone Marrow Transplant Service with teaching responsibilities for fellows, residents and mid-level providers.
2006 - 2011 "Immunobiology of Bone Marrow Transplantation", MCW Hematology/Oncology Fellow Core Education Session, 1 lecture/year
03/07/2012 “CMV Infection after Allogeneic Bone Marrow Transplantation”, Medical Student Lecture
03/21/2013 “Translational Research: Why? Where? How?”, MSTP Program Pathway Meeting
 

EXTRAMURAL TEACHING:
Community/Lay Public
10/06/2009 Milwaukee Lutheran High School, Milwaukee, WI, “Role of Radiation in the Therapy of Medical Diseases”, Physics Class
 

MCW STUDENTS, FACULTY, RESIDENTS AND CLINICAL/RESEARCH FELLOWS MENTORED:
Medical Students
Amar Patel, Medical College of Wisconsin, 1999
Stephen Miller, Medical College of Wisconsin, 2001, Selected as recipient for one of the top 3 poster presentations for summer research.
Jon Anderson, Medical College of Wisconsin, 2006
Anoop Patel, Medical College of Wisconsin, 2008
Scott Kagie, Medical College of Wisconsin, 2009 - 2010, Honors Program, T35 NHLBI-funded
Chelsea Tessler-Verville, Medical College of Wisconsin, 2011, Honors Program, T35 NHLBI-funded, First Place (out of 95 students), Medical Student Research Day, 2011, Physician-Scientist Pathway Advisor 2011-2014
Lindsay Hammons, Medical College of Wisconsin, 2014, Honors Program, T35 NHLBI-funded Physician-Scientist Pathway Advisor 2013- 2014
Ellen Arndt, Medical College of Wisconsin, 2018 - 2019, Research Honors Program, T35 NHLBI-funded Research Project: “Delineating the pathophysiology of neuroinflammation and the role of endocannabinoid signaling in graft versus host disease after allogeneic hematopoietic stem cell transplantation”
Sonali Srivastava, Medical College of Wisconsin, 2019, T35 NHLBI-funded, Research Project: “Role of Interleukin 23 in indirect alloantigen presentation in the gastrointestinal tract during disease”
Lorraine Dang, Medical College of Wisconsin, 2021 - 2023, Physician Scientist Pathway Advisor 2021-2023 Research Honors Program Research Project: “Role of Interleukin 27 signaling pathway in the regulation of regulatory T cell survival and metabolism”
 
Graduate Students
Students Advised
Luke Drury, Medical College of Wisconsin, 2006
Fallon Noto, Medical College of Wisconsin, 2006
Aaron Mull, Medical College of Wisconsin, 2007
Fengie Lu, Medical College of Wisconsin, 2007
Steven Leonardo, Medical College of Wisconsin, 2008
Lily Du, Medical College of Wisconsin, 2008
Amy Beres, Medical College of Wisconsin, 2008 - 2013, Merit Award, MCW Research Day, 2010 American Society of Hematology Travel Award, 2010 Best Abstract Award, MCW Committee on Immunology Conference, 2011 American Society of Hematology Travel Award, 2011 MCW Joseph R Pabst Publication Award, 2012 Outstanding Thesis Dissertation, 2013 (second place) Current Position: Director of Oncology Research, Aurora Research Institute, Milwaukee, WI
Lynsi Lowenhagen, Medical College of Wisconsin, 2009 - 2010, withdrew from graduate school
Olena Wiedemayer, Medical College of Wisconsin, 2010
Alexandra Chadwick, Medical College of Wisconsin, 2010
Alison Bartoszek, Medical College of Wisconsin, 2011
Patrick Gonyo, Medical College of Wisconsin, 2011
Bret Deml, Medical College of Wisconsin, 2012
James Miller, Medical College of Wisconsin, 2012
Emily Gronseth, Medical College of Wisconsin, 2013
Cheng-Yin Yuan, Medical College of Wisconsin, 2014 - 2020 Targeting the Type 2 Cannabinoid Receptor in Mediating the Severity of Acute and Chronic GVHD”, April 8, 2020, Poster Presentation, Tandem Transplantation Meeting, Salt Lake City, 2017 Poster Award Winner, MCW 28th Annual Graduate School Poster Session Competition, “The type 2 cannabinoid receptor regulates the severity of acute and chronic graft versus host disease in mice”, 2018 Current Position: Research Scientist, Amgen, San Francisco, CA
Clint Piper, Medical College of Wisconsin, 2015 “Mechanistic Insights of GM-CSF-Induced Gastrointestinal Inflammation in Acute Graft Versus Host Disease”, Doctoral Candidate 2016-2020 Center of Immunology Scientific Retreat, Oral Presentation, 2018 American Society of Hematology Abstract Achievement Award, 2018 American Society of Hematology Oral Presentation, 2018 American Society of Hematology Oral Presentation, 2019 Current Position: Pediatric Residency Program, University of Pittsburgh, Pittsburg, PA
Wen Zhu, Medical College of Wisconsin, 2016
Nicole Minton, Medical College of Wisconsin, 2018
Qian Liu, Medical College of Wisconsin, 2018
Demetra Korkov, Medical College of Wisconsin, 2019
Valeria Robleto, Medical College of Wisconsin, 2019
Yiwei Kong, Medical College of Wisconsin, 2019
Emma Hainsworth, Medical College of Wisconsin, 2020 “Characterization of an IL-7 Responsive, GM-CSF+ CD4+ T cell Population that Promotes GI Inflammation in Acute GVHD", Masters Candidate 2020-2021 Current Position: Scientist, Millipore Sigma, Milwaukee, WI
Katie Smith, Medical College of Wisconsin, 2021
Akanksha Gurtu, Medical College of Wisconsin, 2021
Lu Zhou, Medical College of Wisconsin, 2021
Fangfei Zhang, Medical College of Wisconsin, 2022
Emmanuella Dwomo Agyei, Medical College of Wisconsin, 2022
Archi Paul, Medical College of Wisconsin, 2023
Malone Friedman, Medical College of Wisconsin, 2023
Miracle Emosivbe, Medical College of Wisconsin, 2023
Mohamad Gadelkarim, Medical College of Wisconsin, 2023, Doctoral Candidate 2024-Pres
Tanya Kozlik, Medical College of Wisconsin, 2023 - Present, Co-Mentor with Dr Anthony Zamora
Leonard Asare, Medical College of Wisconsin, 2023
PhD Students Advised
Tyce Kearl, Medical College of Wisconsin, 2007
Bryce Schuler, Medical College of Wisconsin, 2009
Committees
Amy Beres, Medical College of Wisconsin, 2008 - 2012 “The Role of Induced Regulatory T Cell Populations in Graft Versus Host Disease Biology”
Cheng Yin-Yuan, Medical College of Wisconsin, 2014 - 2020 “Targeting the Type 2 Cannabinoid Receptor in Mediating Acute and Chronic Graft versus Host Disease”
Clint Piper, Medical College of Wisconsin, 2016 - 2020 “Mechanistic Insights of GM-CSF-Induced Gastrointestinal Inflammation in Acute Graft Versus Host Disease”
Emma Hainstock, Medical College of Wisconsin, 2019 - 2021 “Characterization of an IL-7 Responsive GM-CSF+ CD4+ T Cell Population that Promotes GI Inflammation in Acute GVHD”
Moujtaba Kasmani, Medical College of Wisconsin, 2019 - 2022 “T Cell Receptor Structure and Signaling Impact CD8 T Cell Fate Decisions in Chronic Inflammatory Settings”
Jian Shen, Medical College of Wisconsin, 2020 - 2022, Transferred to Northwestern Medical Center Graduate Program due to mentor recruitment.
 
Postdoctoral Students
Elizabeth Tivol, Medical College of Wisconsin, 2002 - 2004, Current Position: Retired from Science
Rupali Das, Medical College of Wisconsin, 2006 - 2009, Winner of MCW Outstanding Women Post-Doctoral Researcher, 2008 MCW Post Doctoral Fellowship Award, 2009 Lady Tata Memorial Trust Fellowship Award, 2009 Current Position: Assistant Professor of Physiology, Michigan State University, Lansing, MI
Will Hallet, Medical College of Wisconsin, 2007 - 2011 Co-Mentor with Dr Bryon Johnson, MCW Post Doctoral Fellowship Award, 2009 Current Position: Senior Biologist, Food and Drug Administration, Washington, DC
Hariharan Subramanian, Medical College of Wisconsin, 2009, Current Position: Assistant Professor of Physiology, Michigan State University, Lansing, MI
Ludovic Belle, Medical College of Wisconsin, 2013 - 2016, MCW Postdoc Travel Award, 2015 American Society of Hematology Abstract Achievement Award, 2015 American Society of Hematology Abstract Achievement Award, 2016 Current Position: Post-Doctoral Fellow, Hematology Research Unit, GIGA-I3, University of Liege, Belgium
Joshua Garlich, Medical College of Wisconsin, 2017 - 2018, Current Position: Senior Research Scientist, Apellis Pharmaceuticals
Wenwen Xu, Medical College of Wisconsin, 2019 - 2021, Current Position: Senior Research Scientist, Abbvie Pharmaceuticals
Aditya Rayasam, Medical College of Wisconsin, 2020 - 2023, Current Position: Senior Scientist, Salk Institute, San Diego, CA
 
Clinical/Research Fellows
Jala Potluri, Medical College of Wisconsin, 1996 Clinical Research Mentor, Current Position: Private Practice, Chicago, IL
Parameswaran Hari, Medical College of Wisconsin, 2003 - 2004 Laboratory Research Fellow, Previous position: Professor of Medicine, Chief of Hematology/Oncology, Medical College of Wisconsin, Milwaukee, WI
Nanveer Rand, Medical College of Wisconsin, 07/2007 - 11/2007 Laboratory Research Fellow, Current Position: Private Practice, Milwaukee, WI
Frank Cornell, Medical College of Wisconsin, 2010 - 2012 Clinical Research Mentor, Thesis: “Engraftment Syndrome after Autologous Stem Cell Transplantation” American Society of Bone Marrow Transplantation Clinical Research Training Course Award 2012 Current Position: Medical Director of US Medical Affairs, AbbVie, Nashville, TN
Hemalatha Rangaran, Medical College of Wisconsin, 2010 - 2012 Laboratory Research Fellow, Research project: “Emergence of T cells that recognize nonpolymorphic antigens during graft versus host disease” American Society of Hematology Travel Award, 2011 Current Position: Assistant Professor of Pediatrics, Nationwide Children’s Hospital, Ohio State University, Columbus, OH
Jonathan Thompson, Medical College of Wisconsin, 2015 - 2017 Clinical Research Mentor, Research project: “Etanercept for the Treatment of Late Onset Idiopathic Pneumonia Syndrome" Medical College of Wisconsin Affiliated Hospitals Research and Quality Award, 2017 Current Position: Assistant Professor of Medicine, Medical College of Wisconsin, Milwaukee, WI
 
Residents
Frank Cornell, Medical College of Wisconsin, 2009
 
Faculty
Xiao Chen, Medical College of Wisconsin, 2010 - 2018, Current Position: Associate Professor of Medicine, Division of Hematology/Oncology, Medical College of Wisconsin Awarded Amy Strelzer Manasevit Research Grant Received First R01 NIH NIAID Grant, 2017-2023
Robert Frank Cornell, Medical College of Wisconsin, 2012 - 2015 Master’s Thesis Advisor, "Engraftment Syndrome and Autologous Graft Versus Host Disease” Current Position: Medical Director, US Medical Affairs, Abbvie
Jay Tichelaar, Medical College of Wisconsin, 2012 - 2014, Assistant Professor of Medicine
Saurabh Chhabra, Medical College of Wisconsin, 2017 - 2019, Assistant Professor of Medicine Current Position: Associate Professor of Medicine, Division of Hematology/Oncology, Mayo Clinic, Phoenix, Arizona
Nirav Shah, Medical College of Wisconsin, 2017 - 2019, Assistant Professor of Medicine Current Position: Associate Professor of Medicine, Director BMT and Cellular Therapy Program, Medical College of Wisconsin
Lyndsey Runaas, Medical College of Wisconsin, 2018 - Present, Assistant Professor of Medicine
Anthony Zamora, Medical College of Wisconsin, 2019 - Present, Assistant Professor of Medicine Project Leader, Riney Foundation Award, 2022-2024
Matthew Kudek, Medical College of Wisconsin, 2021 - Present, Assistant Professor of Pediatrics
 

EXTRAMURAL STUDENTS, FACULTY, RESIDENTS, AND CLINICAL/RESEARCH FELLOWS MENTORED:
Graduate Students
Committees
Eileen Burd, Medical College of Wisconsin, Dept of Pathology, 1991 - 1993 “Human Herpesvirus Six - Associated Dysfunction of Cells of the Monocyte/Macrophage Lineage”
Stephen Jones, Jefferson Medical College, 2003 - 2004 “The Immunobiology of Acute Graft Versus Host Disease across Minor Histocompatibility Antigen Barriers”
Melinda Rokos Keith, University of Miami, 05/29/2007 “The contribution of homeostatically expanded donor CD8 T cells to host reconstitution following syngeneic hematopoietic cell transplantation”
 


BIBLIOGRAPHY
Refereed Journal Publications/Original Papers
1. Qazi R, Chuang J-LC, and Drobyski WR. Estrogen receptors and patterns of relapse in breast cancer. Arch Int Med, 144:2365-2370, 1984.
2. Drobyski WR and Qazi R. Spontaneous regression in non-Hodgkin's lymphoma: clinical and pathogenetic considerations. Am J Hematol 31:138-141, 1989.
3. Drobyski WR, Thibodeau S, Truitt RL, Baxter-Lowe LA, Gorski J, Jenkins R, Gottschall J, and Ash RC. Third party-mediated graft rejection and graft-versus-host disease after T-cell depleted bone marrow transplantation as demonstrated by hypervariable DNA probes and HLA-DR polymorphism. Blood 74:2285-2294, 1989.
4. Drobyski WR, Piaskowski V, Ash RC, Casper JT, and Truitt RL. Preservation of lymphokine-activated killer (LAK) activity following T-cell depletion of human bone marrow. Transplantation 50:625-632, 1990.
5. Knox KK, Drobyski WR, and Carrigan DR. Cytomegalovirus dually resistant to ganciclovir and foscarnet. Lancet 337:1292-1293, 1991.
6. Drobyski WR, Gottlieb M, Carrigan D, Ostberg L, Grebeneau M, Schran H, Magid P, Ehrlich P, Nadler PI, and Ash RC. Phase I study of safety and pharmacokinetics of a human anti-cytomegalovirus monoclonal antibody in allogeneic marrow transplant recipients. Transplantation 51:1190-1196, 1991.
7. Drobyski WR, Knox KK, Carrigan DR, and Ash RC. Foscarnet therapy of ganciclovir-resistant cytomegalovirus in marrow transplantation. Transplantation 52:155-157, 1991.
8. Carrigan DR, Drobyski WR, Russler SK, Tapper MA, Knox KK, and Ash RC. Interstitial pneumonitis due to human herpes virus-6 (HHV-6) in marrow transplantation. Lancet 338:147-149, 1991.
9. Drobyski WR, LeFever AV, and Truitt RL. Regulation of lymphokine-activated killer activity in T-replete and T-cell depleted human bone marrow by interleukin 4. Exp Hematol 19:950-957, 1991.
10. Drobyski WR, Roth M, Thibodeau S, and Gottschall J. Molecular remission occurring after donor leukocyte infusions for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplant. Bone Marrow Transplant 10:301-304, 1992.
11. Drobyski WR, Dunne WM, Burd EM, Knox KK, Horowitz MM, Ash RC, Flomenberg N, and Carrigan DR. Human herpesvirus-6 infection in allogeneic bone marrow transplant recipients. I. Evidence of a marrow suppressive role for HHV-6 in vivo. J Infect Dis 167:735-739, 1993.
12. Drobyski WR, Baxter-Lowe LA, and Truitt RL. Detection of residual leukemia by the polymerase chair reaction and sequence-specific oligonucleotide probe hybridization after allogeneic bone marrow transplantation for AKR leukemia: A murine model for minimal residual disease. Blood 81:551-559, 1993.
13. Drobyski WR, Eberle M, Majewski D, and Baxter-Lowe LA.. Prevalence of human herpesvirus six variant A and B infections in bone marrow transplant recipients as determined by polymerase chain reaction and sequence-specific oligonucleotide probe hybridization. J Clin Micro 31:1515-1520, 1993.
14. Drobyski WR, Keever CA, Roth MS, Koethe S, Hanson G, McFadden P, Gottschall JL, Ash RC, Van Tuinen P, Horowitz MM, and Flomenberg N. Salvage immunotherapy using donor leukocyte infusions as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation: Efficacy and toxicity of a defined T-cell dose. Blood 82:2310-2318, 1993
15. Johnson BJ, Drobyski WR and Truitt RL. Delayed infusion of normal donor cells after MHC-matched bone marrow transplantation provides an antileukemia reaction without graft-versus-host disease. Bone Marrow Transplant 11: 329, 1993.
16. Flomenberg P, Babbitt J, Drobyski WR, Ash RC, Carrigan DR, Sedmark GV, Camitta B, Horowitz MM and Casper JT. Risk of adenovirus disease in bone marrow transplant recipients. J Infect Dis 169:775-781, 1994.
17. Drobyski WR, Knox KK, Majewski D and Carrigan DR. Fatal encephalitis due to variant B human herpesvirus six in a bone marrow transplant recipient. New Engl J Med 330:1356-1360, 1994.
18. Drobyski WR, Ash RC, Casper JT, McAuliffe T, Horowitz MM, Lawton C, Keever C, Baxter-Lowe LA, Camitta B, Garbrecht F, Pietryga D, Hansen R, Chitambar CR, Anderson T and Flomenberg N. Effect of T-cell depletion as graft-versus-host disease prophylaxis on engraftment, relapse, and disease-free survival in unrelated marrow transplantation for chronic myelogenous leukemia. Blood 83:1980-1987, 1994.
19. Hessner MJ, Roth MS, Drobyski WR and Baxter-Lowe LA. Development of a sensitive, highly controlled assay for molecular detection of the Philadelphia chromosome in patients with chronic myelogenous leukemia. Genet Anal Tech Appl 11:90-94, 1994.
20. Drobyski WR, Keever CA, Hanson G, McAuliffe T and Griffith OW. Inhibition of nitric oxide production is associated with enhanced weight loss, decreased survival and impaired alloengraftment in mice undergoing graft-versus-host disease after bone marrow transplantation. Blood 84:2363-2373, 1994.
21. Datta YH, Adams PT, Drobyski WR, Ethier SP, Terry VH, and Roth MS. Sensitive detection of occult breast cancer by the reverse transcriptase polymerase chain reaction. J Clin Oncol 12:475-482, 1994.
22. Casper J, Camitta B, Truitt R, Baxter-Lowe LA, Bunin N, Lawton C, Murray K, Hunter J, Pietryga D, Garbrecht F, Keever C, Drobyski W, Horowitz M, Flomenberg N, Ash R. Unrelated bone marrow transplants for children with leukemia or myelodysplasia. Blood 85:2354-2363, 1995.
23. Baxter-Lowe LA, Keever C, Dinaver D, Davies T, Johnson K, Camitta B, Drobyski WR, Garbrecht F, Horowitz M, Pietryga D, Casper J, and Flomenberg N. Use of solid phase automated sequencing to define HLA disparity between bone marrow donors and recipients. Transplant Proc 27:1377-1378, 1995.
24. Sarode R, McFarland JG, Flomenberg N, Casper JT, Cohen E, Drobyski W, Ash R, Horowitz M, Camitta B, Lawton C, Garbrecht F, Gottschall J. Therapeutic plasma exchange does not appear to be effective in the management of thrombocytopenic purpura/hemolytic uremic syndrome following bone marrow transplantation. Bone Marrow Transplant 16:271-275, 1995.
25. Hessner MJ, Endean DJ, Casper JT, Horowitz MM, Keever-Taylor CA, Roth M, Flomenberg N, and Drobyski WR. Use of unrelated marrow grafts compensates for reduced graft-versus-leukemia reactivity after T-cell depleted allogeneic marrow transplantation for chronic myelogenous leukemia. Blood 86:3987-3996, 1995.
26. Drobyski WR, Potluri J, Sauer D, and Gottschall J. Autoimmune hemolytic anemia following T-cell depleted allogeneic bone marrow transplantation. Bone Marrow Transplant 17:1093-1099, 1996.
27. Drobyski WR and Majewski D. Treatment of donor mice with an  T-cell receptor monoclonal antibody induces prolonged T-cell nonresponsiveness and effectively prevents lethal graft-versus-host disease in murine recipients of MHC-matched and MHC-mismatched marrow grafts. Blood 87:5355-5369, 1996.
28. Drobyski WR, Ul-Haq R, Majewski D, and Chitambar C. Modulation of in vitro and in vivo T cell responses by transferrin-gallium and gallium nitrate. Blood 88:3056-3064, 1996.
29. Collins R, Shpilberg O, Drobyski W, Porter D, Giralt S, Champlin R, Wolff S, Hu W, Blume K, Verfaille C, List A, Ognoskie N, Chetrit A, Antin J and Nemunaitis J. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol 15:433-444, 1997.
30. Drobyski WR and Majewski D. Donor  T lymphocytes promote allogeneic engraftment across the major histocompatibility barrier in mice. Blood 89:1100-1109, 1997.
31. Kawanishi Y, Passweg J, Drobyski WR, Rowlings P, Cook-Craig A, Casper J, Pietryga D, Garbrecht F, Camitta B, Horowitz M, Juckett M, Margolis D, Flomenberg N, and Keever-Taylor CA. Effect of T cell subset dose on outcome following T-cell depleted bone marrow transplantation. Bone Marrow Transplant 19:1069-1077, 1997.
32. Drobyski WR, Endean DJ, Klein JP, and Hessner MJ. Detection of BCR/ABL RNA transcripts using the polymerase chain reaction is highly predictive for relapse in patients transplanted with unrelated marrow grafts for chronic myelogenous leukemia. Br J Haematol 98:458-466, 1997.
33. Lawton CA, Cohen EP, Murray KJ, Derus SW, Casper JT, Drobyski WR, Horowitz MM, and Moulder JE. Long term results of selective renal shielding in patients undergoing total body irradiation in preparation for bone marrow transplantation. Bone Marrow Transplant 20:1069-1074, 1997.
34. Juckett M, Rowlings P, Hessner M, Keever-Taylor C, Burns W, Camitta B, Casper J, Drobyski WR, Hanson G, Horowitz M, Lawton C, Margolis D, Pietryga D, and Vesole D. T-Cell depleted allogeneic bone marrow transplantation for high risk non-hodgkin lymphoma: Clinical and molecular follow-up. Bone Marrow Transplant 21: 893-899, 1998.
35. Link CJ, Burt RK, Traynor AE, and Drobyski WR. Adoptive Immunotherapy for Leukemia: Donor Lymphocytes Transduced with the Herpes Thymidine Kinase Gene for Remission Induction. Human Gene Ther 9:115-134, 1998.
36. Drobyski WR, Pelz C, Kabler-Babbitt C, Hessner M, Baxter-Lowe LA, and Keever-Taylor CA. Successful unrelated marrow transplantation for patients with chronic myelogenous leukemia over the age of forty. Biol Blood Marrow Transplant 4: 3-12, 1998.
37. Drobyski WR and Hessner M. The use of the polymerase chain reaction to predict for subsequent relapse in unrelated marrow transplantation for chronic myelogenous leukemia. Leuk Lymphoma 31: 317-323, 1998.
38. Drobyski WR, Majewski D, Ozker K, and Hanson G. Ex vivo anti-CD3 antibody activated donor T cells have a reduced ability to cause lethal murine graft-versus-host disease but retain their ability to facilitate alloengraftment. J Immunol 161: 2610-2619, 1998.
39. Porter DL, Collins RH, Shpilberg O, Drobyski WR, Sproules A and Antin JH. Long term follow up of 66 patients who achieved complete remission after donor leukocyte infusions for relapse after allogeneic bone marrow transplantation. Biol Blood Marrow Transplant 5:253-261, 1999.
40. Drobyski WR, Hessner MJ, Klein JP, Kabler-Babbitt C, Vesole DH and Keever-Taylor CA. T cell depletion plus salvage immunotherapy with donor leukocyte infusions as a strategy to treat chronic phase chronic myelogenous leukemia patients undergoing HLA-identical sibling marrow transplantation. Blood 94: 434-441, 1999.
41. Drobyski WR, Majewski D and Hanson G. Graft facilitating doses of ex vivo activated gamma delta T cells do not cause lethal murine graft-versus-host disease. Biol Blood Marrow Transplant 5: 222-230, 1999.
42. Burt RK, Drobyski WR and Link CJ. Herpes simplex thymidine kinase transgenic donor lymphocytes. Bone Marrow Transplant 24: 1043-1051, 1999.
43. Porter DL, Collins RH, Hardy C, Kernan NA, Drobyski W, Giralt S, Flowers MED, Casper J, Leahey A, Parker P, Mick R, Bate-Boyle B, King R and Antin JH. Treatment of relapsed leukemia after unrelated donor marrow transplantation with unrelated donor leukocyte infusions. Blood 95: 1214-1221, 2000.
44. Champlin RE, Passweg JR, Zhang M, Rowlings PA, Pelz C, Atkinson KA, Barrett AJ, Cahn J-Y, Drobyski WR, Gale RP, Goldman JM, Gratwohl A, Gordon-Smith EC, Henslee-Downey PJ, Herzig RH, Klein JP, Marmont AM, O'Reilly RJ, Ringden O, Slavin S, Sobocinski KA, Speck B, Weiner RS, Horowitz MM. T cell depletion of bone marrow transplants for leukemia from donors other than HLA-identical siblings: Advantage of T cell antibodies with narrow specificities. Blood 95: 3996-4003, 2000.
45. Luhm RA, Bellissimo DB, Uzgiris AJ, Drobyski WR and Hessner MJ. Quantitative evaluation of post bone marrow transplant engraftment status using fluorescently-labeled variable number of tandem repeats (VNTRs). Molecular Diagnosis 5:129-138, 2000.
46. Drobyski WR, Vodanovic-Jankovic S and Klein J. Adoptively transferred  T cells indirectly regulate murine graft versus host reactivity following donor leukocyte infusion therapy in mice. J Immunol 165:1634-1640, 2000.
47. Drobyski WR. Evolving strategies to address adverse transplant outcomes associated with T cell depletion. J Hematother Stem Cell Research 9: 327-337, 2000.
48. Collins RH, Goldstein S, Giralt S, Levine J, Porter D, Drobyski W, Barrett J, Johnson M, Kirk A, Horowitz M and Parker P. Donor leukocyte infusions in acute lymphocytic leukemia. Bone Marrow Transplant 5: 511-516, 2000.
49. Salama M, Nevill T, Marcellus D, Parker P, Johnson M, Kirk A, Porter D, Giralt S, Levine JE, Drobyski W, Barrett J, Horowitz M and Collins R. Donor leukocyte infusions for multiple myeloma. Bone Marrow Transplant 26: 1179-1184, 2000.
50. Drobyski WR, Morse HC, Burns WH, Casper JT and Sandford G. Protection from lethal graft versus host disease without compromise of alloengraftment using transgenic donor T cells expressing a thymidine kinase suicide gene. Blood 97: 2506-2513, 2001.
51. Keever-Taylor CA, Bredeson C, Vesole DH and Drobyski WR. Analysis of risk factors for the development of GVHD after T cell depleted allogeneic BMT: Effect of HLA disparity, ABO incompatibility and method of T cell depletion. Biol Blood Marrow Transplant 7: 620-630, 2001.
52. Levine JE, Braun T, Penza SL, Beatyy P, Cornetta K, Martino R, Drobyski WR, Barrett AJ, Porter DL, Giralt S, Leis J, Johnson M, Horowitz M and Collins RH. A prospective trial of chemotherapy and donor leukocyte infusions for relapse of advanced myeloid malignancies following allogeneic stem cell transplantation. J Clin Oncol 20: 405-412, 2002.
53. Drobyski WR, Klein J, Flomenberg N, Pietryga D, Vesole DH, Margolis DA and Keever-Taylor CA. Superior survival associated with transplantation of matched unrelated versus one antigen mismatched unrelated or highly HLA-disparate haploidentical family donor marrow grafts for the treatment of hematologic malignancies: Establishing a treatment algorithm for recipients of alternative donor grafts. Blood 99: 806-814, 2002.
54. Drobyski WR, Komorowski R, Logan B and Gendelman M. Role of the passive apoptotic pathway in graft versus host disease. J Immunol 169: 1626-1633, 2002.
55. Drobyski WR and Gendelman M. Regulation of alloresponses after bone marrow transplantation using donor T cells expressing a thymidine kinase suicide gene. Leuk Lymp 43: 2011-2016, 2002.
56. Rosenblum M, Drobyski WR, Keever-Taylor CA and Chang C. Concurrent presence of both patient and donor t(14;18) in a follicular lymphoma patient after undergoing allogeneic BMT-Implications for miminal residual disease detection post-transplant. Bone Marrow Transplant 31: 947-949, 2003.
57. Drobyski WR, Gendelman M, Vodanovic-Jankovic and Gorski J. Elimination of leukemia in the absence of lethal graft versus host disease. J Immunol 170: 3046-3053, 2003.
58. Burt RK*, Drobyski W*, Seregina T, Traynor A, Oyama Y, Keever-Taylor C, Stefka J, Kuzel T, Burns W and Link C. Herpes simplex thymidine kinase gene transduced donor lymphocyte infusions for relapsed hematologic malignancies following allogeneic hematopoietic stem cell transplantation. Exp Hematol 31: 903-910, 2003. (* Both authors contributed equally to this work).
59. Gendelman M, Yassai M, Tivol E, Krueger A, Gorski J and Drobyski WR. Selective elimination of alloreactive donor T cells attenuates graft versus host disease and enhances T cell reconstitution. Biol Blood Marrow Transplant 9: 742-752, 2003.
60. Gendelman M, Hecht T, Logan B, Vodanovic-Jankovic S, Komorowski R and Drobyski WR. Host conditioning is a primary determinant in modulating the effect of interleukin 7 on murine graft versus host disease. J Immunol 172: 3328-3336, 2004.
61. Drobyski WR. The Role of Allogeneic Transplantation in High-Risk Acute Myelogenous Leukemia. Leukemia 18: 1565-1568, 2004 (Keynote Address).
62. Hari P, Logan B and Drobyski WR. Temporal discordance between graft versus leukemia and graft versus host responses: A strategy for the separation of GVL/GVH reactivity? Biology Blood Marrow Transplantation 10: 743-747, 2004.
63. Gendelman M, Halligan N, Komorowski R, Logan B, Murphy WJ, Blazar BR, Pritchard K and Drobyski WR. Phenyl-tert-butyl-nitrone protects syngeneic marrow transplant recipients from the lethal cytokine syndrome occurring after agonistic CD40 antibody administration. Blood 105: 428-431, 2005.
64. Tivol E, Komorowski R and Drobyski WR. Emergent autoimmunity in graft versus host disease. Blood 105: 4887-4893, 2005.
65. Hari P and Drobyski WR. Bortezomib in the management of relapsed multiple myeloma. In Scope Oncology and Hematology 2: 3-6, 2005.
66. Vodanovic-Jankovic S, Hari P, Jacobs P, Komorowski R and Drobyski WR. NF-B as a target for the prevention of graft versus host disease: Comparative efficacy of bortezomib and PS-1145. Blood 107:827-834, 2006.
67. Vodanovic-Jankovic S and Drobyski WR. Gamma delta T cells do not require fully functional cytotoxic pathways or the ability to recognize recipient alloantigens to prevent graft rejection. Biol Blood Marrow Transplant 12: 1125-1134, 2006.
68. Cohen EP, Drobyski WR and Moulder JE. Sixteen-fold increase in end stage renal disease after hematopoietic stem cell transplantation. Bone Marrow Transplant 39: 571-572, 2007.
69. Gorski J, Chen X, Gendelman M, Yassai M, Krueger A, Tivol E, Logan B, Komorowski R, Vodanovic-Jankovic S, and Drobyski WR. Homeostatic expansion and repertoire regeneration of donor T cells during graft versus host disease is constrained by the host environment. Blood 109: 5502-5510, 2007.
70. Chen X, Vodanovic-Jankovic S, Johnson B, Keller M, Komorowski R, Drobyski WR. Absence of regulatory T cell control of TH1 and TH17 cells is responsible for the autoimmune-mediated pathology in chronic graft versus host disease. Blood 110: 3804-3813, 2007. Recognized by Faculty 1000 Biology as a recommended paper of interest August 24, 2007; http://www.f1000biology.com/article/id/1089415
71. Cohen EP, Irving AA, Drobyski WR, Klein JP, Passweg J, Talano JM, Juckett MB, and Moulder JE. Captopril to mitigate chronic renal failure after hematopoietic stem cell transplantation: a randomized controlled trial. Int J Rad Oncol Biol Phys 70: 1546-1551, 2008.
72. Levine JE, Barrett AJ, Zhang MJ, Arora M, Pulsipher MA, Bunin N, Fort J, Loberiza F, Porter D, Giralt S, Drobyski W, Wang D, Pavletic S, Ringden O, Horowitz M, Collins R. Donor leukocyte infusions to treat hematologic malignancy relapse after allogeneic stem cell transplantation in a pediatric population. Bone Marrow Transplant 42:201-205, 2008.
73. Drobyski WR, Hari P, Keever-Taylor CA, Komorowski R, Grossman W. Severe autologous graft versus host disease after hematopoietic progenitor cell transplantation for multiple myeloma. Bone Marrow Transplant 43: 169-177, 2009.
74. Das R, Chen X, Komorowski R, Hessner MJ, Drobyski WR. Interleukin 23 secretion by donor antigen presenting cells is critical for organ-specific pathology in graft versus host disease. Blood 113: 2352-2362, 2009.
75. Chen X, Das R, Komorowski R, Beres A, Hessner MJ, Mihara M, Drobyski WR. Blockade of interleukin 6 signaling augments regulatory T cell reconstitution and attenuates the severity of graft versus host disease. Blood 2009; 114: 891-900.Recognized by Faculty 1000 Biology as a recommended paper of interest June 9, 2009; http://www.f1000biology.com/article/id/1161030
76. Filicko-O'Hara J, Filicko J, Grosso D, Flomenberg PR, Friedman TM, Brunner J, Drobyski W, Ferber A, Kahkniashvili I, Keever-Taylor C, Moorkerjee B, Talano J,A, Wagner JL, Korngold R, Flomenberg N. Anti-viral responses following LLME-treated lymphocyte infusions: Graft versus infection without graft versus host disease. Biol Blood Marrow Transplant 15: 1609-1619, 2009.
77. Chen X, Das R, Komorowski R, van Snick J, Uyttenhove C, Drobyski WR. Interleukin 17 is not required for autoimmune-mediated pathological damage during chronic graft versus host disease. Biol Blood Marrow Transplant 16: 123-128, 2010.
78. Johnson B, Drobyski W, Blazar B, Korngold R. Robert Truitt Tribute. Biol Blood Marrow Transplant 16: 143-144, 2010.
79. Sukumaran S, George B, Nair H, Drobyski WR. Posterior reversible encephalopathy syndrome in association with high dose steroids after autologous peripheral blood stem cell transplantation. Bone Marrow Transplant 45:779-80, 2010.
80. Gress RE, Emerson SG, Drobyski WR. Immune reconstitution: How it should work, what's broken, and why it matters. Biol Blood Marrow Transplant 16: S133-S137, 2010.
81. Das R, Komorowski R, Hessner MJ, Subramanian H, Huettner CS, Cua D, Drobyski WR. Blockade of interleukin 23 signaling results in targeted protection of the colon and allows for separation of graft versus host and graft versus leukemia responses. Blood 115: 5249-5258, 2010.
82. Cogbill CH, Drobyski WR, Komorowski RA. Gastrointestinal pathology of autologous graft versus host disease following hematopoietic stem cell transplantation: a clinicopathologic study of 17 cases. Mod Pathol 24: 117-125, 2011.
83. Hallett WHD, Jing W, Drobyski WR, Johnson BD. Immunosuppressive effects of multiple myeloma are overcome by PD-L1 blockade. Biol Blood Marrow Transplant 2011 (in press).
84. Beres A, Komorowski R, Mihara M, Drobyski WR. Instability of Foxp3 expression limits the ability of induced regulatory T cells to mitigate graft versus host disease. Clin Cancer Res 2011 (in press).
 
Books, Chapters, and Reviews
1. Truitt RL, Horowitz MM, Atasoylu AA, Drobyski WR, Johnson BD, and LeFever AV. Graft-versus-leukemia effect of allogeneic bone marrow transplantation: Clinical and experimental aspects of late leukemia relapse. In: Cellular and Immune Mechanisms and Tumor Dormancy, T.H. Stewart, E.F. Wheelock, Eds. CRC Press, 1992, pp 111-128.
2. Cook-Craig A, Owen A, Reeder G, Drobyski WR, Horowitz M, Brunner J, Flomenberg N, and Keever C. Component processing and intraoperative autotransfusion during bone marrow harvest. Fourth International Symposium on Advances in Bone Marrow Purging and Processing. Prog Clin Biol Res 389:613-619, 1994.
3. Drobyski WR. Adoptive immunotherapy using donor leukocyte infusions to treat relapsed hematologic malignancies after allogeneic bone marrow transplantation in Allogeneic Hematopoietic Stem Cell Transplantation (ed. R Burt), Kluwer Academic Publishers, pp.233-266, 1999.
 
Abstracts
1. Drobyski WR, Thibodeau S, Jenkins R, Gottschall J, Truitt RL, and Ash RC: Novel "third party" mediated graft rejection (and graft-versus-host disease) following T-cell depleted bone marrow transplantation as demonstrated by a hypervariable "mini-satellite" DNA probe. 33rd Annual Meeting of the American Society of Hematology, San Antonio, Texas, December 1988 (Poster Presentation).
2. Drobyski WR, LeFever A, and Truitt RL: Kinetic analysis of lymphokine regulation of bone marrow-derived LAK cells. Society of Biologic Therapy, Williamsburg, Virginia, November, 1989, (Poster Presentation).
3. Drobyski WR, Piaskowski V, Ash RC, and Truitt RL: Preservation of lymphokine-activated killer (LAK) activity following T-cell depletion of human bone marrow. UCLA Bone Marrow Transplantation Symposia, Keystone, Colorado, January 1990 (Poster Presentation).
4. Drobyski WR, Gottlieb M, Carrigan DR, Ostberg L, Grebeneau M, Schran H, Magid P, Ehrlich P, Nadler PI, and Ash RC: Phase I study of safety and pharmacokinetics of a human anti-cytomegalovirus monoclonal antibody in allogeneic marrow transplant recipients. International Society for Experimental Hematology, Seattle, Washington, August 1990. (Poster Presentation).
5. Carrigan DR, Russler SK, Drobyski WR, Knox KK, and Tapper MA: Human herpesvirus-6 (HHV-6)-associated interstitial pneumonitis in two bone marrow transplant patients. Fifteenth International Herpesvirus Workshop, Washington, D.C., August 1990.
6. Truitt RL, Casper JT, Drobyski WR, and Ash RC: Clinical and laboratory investigations in T-cell depleted allogeneic bone marrow transplantation. Proc. 28th Annual Meeting, Association for Gnotobiotics, Buffalo, New York, October 1990.
7. Drobyski WR, McOlash L, Ash RC, and Truitt RL: Comparative analysis of T-cell depletion techniques: Implications for the antileukemic efficacy of T-cell depleted allogeneic bone marrow transplantation. 34th Annual Meeting of the American Society of Hematology, Denver, Colorado, December 1991. (Poster Presentation).
8. Drobyski WR, Dunne WM, Burd E, Knox KK, and Carrigan DR: Human Herpesvirus 6 Infection in Allogeneic Bone Marrow Transplant Recipients. UCLA Bone Marrow Transplant Symposia, Keystone, Colorado, January 1992. (Oral Presenatation).
9. Drobyski WR, Dunne WM, Burd, E, Knox KK, Ash RC, Horowitz MM, Flomenberg N, and Carrigan DR: Human Herpesvirus (HHV-6) infection in bone marrow transplant recipients. I. Evidence of a marrow suppressive role for HHV-6 in vivo. Seventeenth International Herpesvirus Workshop, Edinburgh, Scotland, July 1992.
10. Drobyski, WR, Keever C, Roth M, Koethe S, Hanson G, McFadden P, Gottschall J, Horowitz M, Ash R, and Flomenberg N: Donor leukocyte infusions as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation. 35th Annual Meeting of the American Society of Hematology, Anaheim, CA, Blood 80:66a, 1992. (Poster Presentation).
11. Baxter-Lowe, LA, Casper J, Flomenberg N, Dinauer D, Camitta B, Drobyski WR, Garbrecht F, Pietryga D, Horowitz M, Anderson T, Chitambar C, Hansen R, Lawton C, Bunin N, Keever C, Pierce K, and Ash RC: Impact of HLA disparity in bone marrow transplantation. Annual Meeting of the American Association of Immunology. J Immunol 150:321a, 1993.
12. Cook-Craig A, Owen A, Reeder G, Drobyski WR, Horowitz M, Brunner J, Flomenberg N, and Keever C: Component processing and intraoperative autotransfusion during bone marrow harvest. International Society of Hematotherapy and Graft Engineering, Orlando, FL, September 1993.
13. Kawanishi Y, Flomenberg N, Craig A, Drobyski WR, Horowitz M, Casper J, Camitta B, Pietryga D, Garbrecht F and Keever C: Effect of T-cell subset content on acute graft-versus-host disease following T-cell depleted bone marrow transplantation. 36th Annual Meeting of the American Society of Hematology, St. Louis, MO, Blood 82:423a, 1993. (Poster Presentation).
14. Hessner MJ, Roth MS, Drobyski WR and Baxter-Lowe LA: Development and implementation of a sensitive highly controlled assay system for molecular detection of the Philadelphia chromosome in patients with chronic myelogenous leukemia. 36th Annual Meeting of the American Society of Hematology, St. Louis, MO, December 1993. (Poster Presentation).
15. Drobyski WR, Ash RC, Casper JT, McAuliffe T, Horowitz MM, Lawton C, Keever C, Baxter-Lowe LA, Camitta B, Garbrecht F, Pietryga D, Hansen R, Chitambar CR, Anderson T and Flomenberg N: Effect of T-cell depletion as graft-versus-host disease prophylaxis on engraftment, relapse, and disease-free survival in unrelated marrow transplantation for chronic myelogenous leukemia. 36th Annual Meeting of the American Society of Hematology, St. Louis, MO, Blood 82:423a, 1993. (Poster Presentation).
16. Sarode R, McFarland JG, Flomenberg N, Casper JT, Cohen E, Drobyski WR, Horowitz M, Camitta B, Garbrecht F, Pietryga D, Lawton C, Ash R, and Gottschall J: Therapeutic plasma exchange is not effective in the management of TTP/HUS following bone marrow transplantation. 36th Annual Meeting of the American Society of Hematology, St. Louis, MO, December 1993. (Poster Presentation).
17. Baxter-Lowe LA, Keever C, Daniels T, Dinauer D, Johnson K, Casper J, Drobyski W, Pietryga D, Garbrecht F, Horowitz M and Flomenberg N: Use of solid phase automated sequencing to define HLA disparity between bone marrow donors and recipients, Fifteenth Congress of the Transplantation Society. Transplant Proc 27:1377-1378, 1994.
18. Drobyski WR, Majewski D, Loebel A, Garbrecht F: Abrogation of lethal graft-versus-host disease (GVHD) in mice by administration of  T-cell receptor modulated T cells. 37th Annual Meeting of the American Society of Hematology, Nashville, TN, Blood 84 (Suppl 1): 97a, 1994. (Poster Presentation).
19. Potluri J, Gottschall J, Sauer D, Drobyski WR: Autoimmune hemolytic anemia (AIHA) following T-cell depleted (TCD) allogeneic bone marrow transplantation (BMT). 37th Annual Meeting of the American Society of Hematology, Nashville, TN, Blood 84 (Suppl 1): 493a, 1994. (Poster Presentation).
20. Keever KA, Kawanishi Y, Wank T, Chaltry M, Craig A, Drobyski WR, Horowitz M, Casper J, Camitta B, Pietryga D, Garbrecht F, Flomenberg N, Baxter-Lowe LA: Correlation of T cell dose and CTL precursor frequency with graft versus host disease and survival after unrelated or partially matched related BMT. American Society of Hematology, Nashville, TN, Blood 84 (Suppl 1): 99a, 1994.
21. Pietryga D, Casper J, Garbrecht F, Camitta B, Drobyski W, Horowitz M, Lawton C, Keever C, Baxter-Lowe L, Murray K, Pierce K, Cadwallader S, McAuliffe T, and Flomenberg N. Haploidentical bone marrow transplantation (BMT) for hematologic malignancies. Blood 84 (Suppl 1): 339a, 1994. (Poster Presentation).
22. Hessner M, Endean D, Casper J, Horowitz M, Taylor C, Roth M, Flomenberg N, and Drobyski W. Use of unrelated marrow grafts compensates for reduced graft-versus-leukemia reactivity after T-cell depleted allogeneic BMT for chronic myelogenous leukemia. 37th Annual Meeting of the American Society of Hematology, Seattle, WA, Blood 86 (Suppl 1): 289a, 1995. (Oral Presentation).
23. Drobyski WR, and Majewski D.  T cells prevent allogeneic marrow graft rejection in mice without causing graft-versus-host disease. 37th Annual Meeting of the American Society of Hematology, Seattle, WA, Blood 86 (Suppl 1): 572a, 1995.
24. Juckett M, Rowlings P, Drobyski W, Horowitz M, Lawton C, Keever C, Pietryga D, Casper J, Camitta B, Margolis D, Hanson G. T-cell depleted allogeneic bone marrow transplant for non-Hodgkin's lymphoma: A single institution experience in 32 patients. 37th Annual Meeting of the American Society of Hematology, Seattle, WA, Blood 86 (Suppl 1): 210a, 1995. (Poster Presentation).
25. Collins R, Shpilberg O, Drobyski W, Porter D, Antin J, Wolff S, Giralt S, Chetrit A, Ognoskie N, Prine S, Nemunaitis J. Donor leukocyte infusion (DLI) for post-bone marrow transplant (BMT) relapse - Retrospective cohort analysis of 141 cases. 37th Annual Meeting of the American Society of Hematology, Seattle, WA, Blood 86 (Suppl 1): 563a, 1995.
26. Kawanishi Y, Wank T, Chaltry M, Craig A, Drobyski W, Horowitz M, Casper J, Camitta B, Pietryga D, Garbrecht F, Flomenberg N, Taylor C. Association of infused T-cell subset dose with acute graft-versus-host disease following transplantation of T-cell depleted bone marrow. Proc American Society for Blood and Marrow Transplantation, Keystone, CO, 1995.
27. Kawanishi Y, Passweg J, Drobyski WR, Cook-Craig A, Casper J, Pietryga D, Garbrecht F, Camitta B, Horowitz M, Juckett M, Margolis D, Rowlings P, Flomenberg N, Keever-Taylor CA. Effect of T-cell subset dose on outcome of T-cell depleted bone marrow transplantation. Biol Blood Marrow Transplant 2:150, 1996.
28. Drobyski WR. Donor lymphocyte infusions for relapsed leukemia. Proceedings of the Sixth Annual Malnati Symposium in the Clinical Sciences: Hematopoietic Stem-cell Transplantation Advances and Controversies, Northwestern University Medical School, Chicago, IL, July 1996.
29. Drobyski WR, Ul-Haq R, Majewski D, Chitambar CR. Gallium nitrate inhibits T cell activation and experimental graft versus host disease in mice. 38th Annual Meeting of the American Society of Hematology, Orlando, FL, Blood 88 (Suppl 1): 229b, 1996. (Poster Presentation).
30. Pietryga D, Casper J, Margolis D, Camitta B, Garbrecht F, Drobyski W, Horowitz M, Burns W, Juckett M, Rowlings P, Passweg J, Lawton C, Taylor C, Baxter-Lowe L, Murray K, Pierce K, McAuliffe T, Flomenberg N. Bone marrow transplantation (BMT) using genotypically haploidentical donors. 38th Annual Meeting of the American Society of Hematology, Orlando, FL, Blood 88 (Suppl 1): 264a, 1996.
31. Drobyski WR, Horowitz M, Pietryga D, Margolis D, Juckett M, Burns W, Camitta B, Rowlings P, Keever-Taylor C, and Casper J. Unrelated donor marrow transplantation for acute myelogenous leukemia (AML), myelodysplasia, and secondary AML. 38th Annual Meeting of the American Society of Hematology, Orlando, FL, Blood 88 (Suppl 1): 269a, 1996. (Poster Presentation).
32. Drobyski WR, Pelz C, Kabler-Babbitt K, Hessner M, and Keever-Taylor C. Successful unrelated marrow transplantation for patients with chronic myelogenous leukemia (CML) over the age of 40. 39th Annual Meeting of the American Society of Hematology, San Diego, CA, Blood 90 (Suppl 1): 107a, 1997. (Poster Presentation).
33. Baxter-Lowe LA, Parrish R, Margolis D, Szmania S, Serynck K, White J, Wank T, Molter M, Hazlett L, Drobyski W, Garbrecht F, Pietryga D, Horowitz M, Camitta B, Vesole D, Burns W, Flomenberg N, Casper J,
34. and Keever-Taylor C. HLA disparity detected by automated nucleotide sequencing may aid in selection of alternative donors. 39th Annual Meeting of the American Society of Hematology, San Diego, CA, Blood 90 (Suppl 1): 109a, 1997.
35. Drobyski, WR, Majewski D, Ozker K, and Hanson G. Ex vivo anti-CD3 antibody activated donor T cells have a reduced ability to cause lethal murine graft-versus-host disease (GVHD) but retain their ability to facilitate alloengraftment. 30th Annual Meeting of the American Society of Hematology, San Diego, CA, Blood 90 (Suppl 1): 396a, 1997. (Oral Presentation).
36. Porter DL, Collins R, Drobyski W, Connors JM, Van Hoef M, and Antin J. Long term follow-up of 55 patients who achieved complete remission (CR) after donor leukocyte infusions (DL) for relapse after allogeneic bone marrow transplantation. 39th Annual Meeting of the American Society of Hematology, San Diego, CA, Blood 90 (Suppl 1): 549a, 1997.
37. Porter D, Collins R, Mick R, Kernan N, Giralt S, Flowers M, Casper J, Drobyski W, Leahey A, Parker P, Bates B, King R, and Antin J. Unrelated donor leukocyte infusions (U-DLI) to treat relapse or EBC-lymphoproliferative disease (EBV-LPD) after unrelated donor bone marrow transplantation (BMT). 39th Annual Meeting of the American Society of Hematology, San Diego, CA, Blood 90 (Suppl 1): 590a, 1997.
38. Margolis D, Gorski J, Truitt R, Taylor C, and Drobyski W. Alterations in T cell repertoire during donor leukocyte infusions (DLI). 1st International Symposium on Minor Histocompatibility Antigens, Bar Harbor, Maine, 1997.
39. Stefka J, Hoeft J, Traynor A, Furtado M, Rosen S, Taylor C, Burns W, Drobyski W, Link C, Seregina T, and Burt Transduction of donor lymphocytes with the herpes simplex thymidine kinase (HStk) gene.1998 IBMTR/ABMTR Participants' Meeting, Keystone, CO, January 1998.
40. Dinauer DM, Drobyski WR, Margolis DA, Casper JT, Keever-Taylor CA and Hessner MJ. Multi-resolution nested primer PCR assay for rapid detection and identification of fungi in human blood. 40th Annual Meeting of the American Society of Hematology, Miami, FL, Blood 92 (Suppl 1): 283a, 1998.
41. Wagner JE, King R, Kollman C, Anasetti C, Antin JH, Casper J, Champlin R, Davies SM, Drobyski W, Fay J, Filipovich A, Heslop H, Karanes C, Kernan N, Nademanee A, Schmeckpeper B and Howe C. Unrelated donor bone marrow transplantation in 5075 patients with malignant and non-malignant disorders: Impact of marrow T cell depletion. 40th Annual Meeting of the American Society of Hematology, Miami, FL, Blood 92 (Suppl 1): 686a, 1998.
42. Drobyski WR, Majewski D, and Hanson G. Graft facilitating doses of ex vivo activated  T cells do not cause lethal murine graft-versus- host disease and thereby have a superior therapeutic index when compared to limiting numbers of naïve  T cells. 40th Annual Meeting of the American Society of Hematology, Miami, FL, Blood 92 (Suppl 1): 720a, 1998. (Oral Presentation).
43. Drobyski WR, Klein J, Pietryga D, Flomenberg N, Kabler-Babbitt, Vesole DH, Margolis DA, Keever-Taylor CA, Horowitz M, Juckett M, Rizzo JD, Bauer D, Burns WH and Casper JT. A comparative analysis of transplant outcomes in patients receiving unrelated versus highly HLA-disparate haploidentical family member donor marrow grafts for the treatment of leukemia. 41th Annual Meeting of the American Society of Hematology, New Orleans, LA, Blood 94: 564a, 1999. (Oral Presentation).
44. Drobyski WR, Agostini T, Burns WH, Morse H and Sandford G. Mitigation of murine graft versus host disease without compromise of alloengraftment using transgenic donor T cells expressing a thymidine kinase suicide gene. 41th Annual Meeting of the American Society of Hematology, New Orleans, LA, Blood 94: 550a, 1999. (Poster Presenatation).
45. Link CJ, Drobyski WR, Traynor AE, Seregina T, Taylor CA, Burns WH, Rosen ST, Burt RK. Adoptive immunotherapy for leukemia: Donor lymphocytes transduced with the herpes simplex thymidine kinase gene. 41th Annual Meeting of the American Society of Hematology, New Orleans, LA, Blood 94: 366a, 1999.
46. Levine JE, Penza S, Topolsky D, Beatyy P, Rifkin R, Giralt S, Porter DL, Drobyski WR, Horowitz MM, Collins RH. Prospective trial of chemotherapy plus donor leukocyte infusions to treat relapsed advanced myeloid leukemia after related bone marrow transplantation. 41th Annual Meeting of the American Society of Hematology, New Orleans, LA, Blood 94: 668a, 1999.
47. Drobyski WR, Morse HC, Burns WH and Sandford G. Modulation of alloengraftment, graft versus host, and graft versus leukemia reactivity using transgeneic donor T cells expressing a thymidine kinase suicide gene: Effect of T cell dose and ganciclovir schedule. 42nd Annual Meeting of the American Society of Hematology, San Francisco, CA, Blood
48. Drobyski WR, Klein J, Pietryga D, Flomenberg N, Kabler-Babbitt C, Vesole D, Margolis D, Keever-Taylor C, Bauer D, Burns W and Casper J. Superior survival associated with transplantation of matched unrelated versus highly HLA-disparate haploidentical family marrow grafts for the treatment of leukemia: Establishing a treatment algorithm for recipients of alternative donor grafts. 42nd Annual Meeting of the American Society of Hematology, San Francisco, CA, (Oral Presentation).
49. Drobyski WR, Gendelman M, Yassai M and Gorski J. Effective T cell reconstitution and retained graft versus leukemia reactivity after transplantation of thymidine kinase gene-modified donor T cells. 43rd Annual Meeting of the American Society of Hematology, Orlando, FL, Blood 98: 390a, 2001.
50. Drobyski WR and Gendelman M. Regulated death of donor T cells mediated by bcl-xL is an integral component of the graft versus host reaction. 43rd Annual Meeting of the American Society of Hematology, Orlando, FL, Blood 98: 650a, 2001.
51. Drobyski WR, Klein J, Flomenberg N, Pietryga D, Vesole D, Margolis D, Keever-Taylor C. Superior survival associated with transplantation of matched unrelated versus one antigen-mismatched unrelated or highly HLA-disparate haploidentical family donor marrow grafts for the treatment of hematological malignancies. 43rd Annual Meeting of the American Society of Hematology, Orlando, FL, Blood 98: 668a, 2001.
52. Burt RK, Drobyski WR, Seregina T, Traynor A, Oyama Y, Keever-Taylor C, Rosen S, Kuzel T, Burns W, and Link C. Anti-tumor effectiveness of herpes simplex thymidine kinase gene transduced donor lymphocyte infusions for relapsed hematological malignancies following allogeneic hematopoietic stem cell transplantation. 43rd Annual Meeting of the American Society of Hematology, Orlando, FL, Blood 98: 698a, 2001.
53. Margolis DA, Molter M, Skonecki J, Zeng H, Giesen B, Drobyski WR, Keever-Taylor CA. Rigorous T cell depletion achieved by single step CD34 selection using the Isolex 300i with version 2.5 software: Experience in healthy donors. 44th Annual Meeting of the American Society of Hematology, Philadelphia, PA, Blood
54. Drobyski WR, Gendelman M, Vodanovic-Jankovic S, and Gorski J. Elimination of leukemia without lethal graft versus host disease. 44th Annual Meeting of the American Society of Hematology, Philadelphia, PA, 2002. (Poster Presentation).
55. Drobyski WR, Hecht T, and Gendelman M. Effect of interleukin 7 on murine graft versus host disease. 44th Annual Meeting of the American Society of Hematology, Philadelphia, PA, 2002. (Poster Presentation).
56. Drobyski WR, Gendelman M, Yassai M, Tivol E, Krueger A, and Gorski J. Selective elimination of alloreactive donor T cells attenuates graft versus host disease and enhances T cell reconstitution. 45th Annual Meeting of the American Society of Hematology Meeting, San Diego, CA, 2003 (Poster Presentation).
57. Thumma S, Hari P, Bredeson C, Drobyski W, Flomenberg N, Horowitz M, Johnson V, Keever-Taylor C, Phillips G, Reece D. Rizzo D, Wade J, Vesole D. Phase I/II trial of dose escalation of melphalan with amifostine cytoprotection supported by autologous hematopoietic stem cell transplant in multiple myeloma, 45th Annual Meeting of the American Society of Hematology Meeting, San Diego, CA, 2003
58. Hari P, Thumma S, Bredeson C, Drobyski W, Horowitz M, Kovatovic K, Olson L, Johnson V, Keever-Taylor C, Rizzo D, Wade J, Vesole D. Paroxysmal atrial fibrillation as a complication of autologous stem cell transplant with higher doses of melphalan in multiple myeloma patients. 45th Annual Meeting of the American Society of Hematology Meeting, San Diego, CA, 2003
59. Hari P, Logan B and Drobyski WR. Temporally discordant graft versus leukemia and graft versus host responses after donor lymphocyte infusion therapy for relapsed chronic myelogenous leukemia. American Society for Blood and Marrow Transplantation, Orlando, FL, 2004 (Poster Presentation).
60. Hari P, Vodanovi-Jankovic S, Jacobs P, Komorowski R and Drobyski WR. NF-B as a target for the prevention of graft versus host disease: Comparative efficacy of bortezomib and PS-1145. American Society of Hematology, Atlanta, GA 2005. (Poster Presentation).
61. Chen X, Gorski J, Gendelman M, Yassai M, Krueger A, Tivol E, Logan B, Komorowski R, Vodanovic-Jankovic S, Drobyski WR. Hoemeostatic expansion and repertoire regeneration of donor T cells during graft versus host disease is constrained by the host environment. 48th Annual Meeting of the American Society of Hematology, Orlando, FL 2006. (Oral Presentation).
62. Haribhai D, Grewal J, Ziegelbauer J, Edwards B, Chen X, Verbsky J, Drobyski W, Chatila TA, Williams CB, Grossman WJ. Role of natural T regulatory cells in preventing myeloproliferative disease. Keystone Symposium of Regulatory T Cells, Vancouver, British Columbia, 2007 (Poster Presentation).
63. Chen X, van Snick J, Uyttenhopve C, Komorowski R, Drobyski WR. Inhibition of interleukin 17 significantly attenuates the severity of autoimmune-mediated pathological dmage in chronic graft versus host disease. 49th Annual Meeting of the American Society of Hematology, Atlanta, GA 2007 (Oral Presentation).
64. Das R, Komorowski R, Ghilardi N, Hessner M, Drobyski WR. Critical role for donor antigen presenting cell secretion of interleukin 23 in the pathophysiology of graft versus host disease of the colon. American Society for Blood and Marrow Transplantation, San Diego, CA 2008 (Oral Presentation).
65. Das R, Komorowski R, Hessner MJ, Drobyski WR. Interleukin 23 secretion by donor antigen presenting cells is critical for organ-specific pathology in graft versus host disease. University of Wisconsin Symposium on Immunology, Madison, WI, 2008 (Poster Presentation).
66. Das R, Chen X, Komorowski R, Hessner MJ, Drobyski WR. Interleukin 23 secretion by donor antigen presenting cells is critical for organ-specific pathology in graft versus host disease. 50th Annual Meeting of the American Society of Hematology, San Francisco, CA 2008 (Oral Presentation).
67. Chen X, Das R, Komorowski R, Mihara M, Drobyski WR. Blockade of interleukin 6 signaling attenuates graft versus host disease by augmenting regulatory T cell reconstitution. 50th Annual Meeting of the American Society of Hematology, San Francisco, CA 2008 (Oral Presentation).
68. Zhu F, Tsao A, Xu H, Drobyski WR, Keever-Taylor CA. Optimization of conditions for the transduction of therapeutic T cells using a lentivirus vector. 15th Annual Meeting of the International Society of Cellular Therapy, San Diego, CA 2009
69. Das R, Komorowski R, Hessner M, Subramanian H, Cua D, Huettner C, Drobyski WR. Blockade of IL-23 signaling results in targeted protection of the colon and allows for separation of graft versus host and graft versus leukemia effects. 51st Annual Meeting of the American Society of Hematology, New Orleans, LA, 2009 (Oral Presentation).
70. Das R, Subramanian H, Komorowski R, Hessner M, Drobyski WR. Blockade of Interleukin 23 signaling allows for separation of GVH and GVL effects in both acute and chronic models of leukemia. Medical College of Wisconsin Annual Research Day, Winner of Outstanding Poster Award for Post Graduate Student in Basic Research, September 2009.
71. Coghill C, Drobyski WR, Komorowski R. Gastrointestinal pathology of autologous graft versus host disease following hematopoietic progenitor cell transplantation. United States and Canadian Academy of Pathology 99th Annual Meeting, Washington DC, March 2010.
72. Hallett, WHD, Drobyski WR, Johnson BD. Blockade of the PD-1 pathway improves immunotherapy for multiple myeloma.
73. Beres A, Komorowski R, Drobyski WR. Stability of Foxp3 expression is a critical factor in the ability of regulatory T cells to mitigate graft versus host disease. 52nd Annual Meeting of the American Society of Hematology, Orlando, FI, 2010 (Oral Presentation).